Document:

EX-10.4

 Exhibit 10.4 

EXECUTION COPY 
 RELIEF
THERAPEUTICS / NEURORX 
 BINDING COLLABORATION AGREEMENT 

This Binding Collaboration Agreement (this “Agreement”), dated as of September 18, 2020 outlines the terms and conditions of
the Collaboration (defined below) between Relief Therapeutics Holding Aktiengesellschaft and its wholly owned subsidiary Therametrics Discovery Aktiengesellschaft (collectively, “Relief”), Swiss corporations, and NeuroRx, Inc.
(“NeuroRx”), a Delaware corporation (each a “Party” and, collectively, the “Parties”). The Parties hereby acknowledge and agree that the terms set forth in that certain
Non-Disclosure Agreement between the Parties, dated as of September 9, 2020, apply to the terms set forth herein. 
  

	1.	 Definitions 

 

	 	1.	 “Affiliate” means, with respect to any Person, another Person which controls, is controlled by or is
under common control with such Person. A Person shall be deemed to control another Person if such Person possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of such Person, whether through the
ownership of voting securities, by contract or otherwise. Without limiting the generality of the foregoing, a Person shall be deemed to control another Person if any of the following conditions is met: (a) in the case of corporate entities,
direct or indirect ownership of at least 50% of the stock or shares having the right to vote for the election of directors, and (b) in the case of non-corporate entities, direct or indirect ownership of
at least 50% of the equity interest with the power to direct the management and policies of such non-corporate entities. The Parties acknowledge that in the case of certain entities organized under the laws of
certain countries outside of the United States, the maximum percentage ownership permitted by law for a foreign investor may be less than 50%, and that in such case such lower percentage shall be substituted in the preceding sentence, provided that
such foreign investor has the power to direct the management and policies of such entity. For purposes of this Agreement, in no event shall Relief or any of its Affiliates be deemed Affiliates of NeuroRx or any of its Affiliates, nor shall NeuroRx
or any of its Affiliates be deemed Affiliates of Relief or any of its Affiliates. 

  

	 	2.	 “BARDA” means the United States Biomedical Advanced Research and Development Authority.

	 	3.	 “CMC” means chemistry, manufacturing and controls. 

 

	 	4.	 “CMO” means contract manufacturing organization. 

 

	 	5.	 “Collaboration” means the development and commercialization of the Product as contemplated under this
Agreement. 

  
 1 

	 	6.	 “Commercialization Plan” means a commercial plan for the Product. 

 

	 	7.	 “COVID-19” means disease, condition, or ailment caused by,
associated with, or reasonably related to, the novel 2019 coronavirus. 

  

	 	8.	 “Development Plan” means a written development plan mutually agreed by the Parties.

  

	 	9.	 “Dr. Javitt” means Jonathan C. Javitt, M.D., M.P.H. 

 

	 	10.	 “EU” means the European Union, as its membership may be constituted from time to time and any
successor thereto. 

  

	 	11.	 “FDA” means the United States Food and Drug Administration or any successor entity thereto.

  

	 	12.	 “Information” means any and all materials, data and other information relating to the subject matter
of this Agreement and including: (a) techniques and data, including screens, models, inventions, methods, test data (including, pharmacological, toxicological and clinical test data), analytical and quality control data, marketing, pricing,
distribution, costs, and sales data, manufacturing information, and patent and legal data or descriptions (to the extent that disclosure thereof would not result in loss or waiver of privilege or similar protection); (b) compositions of matter,
including compounds, biological materials and assays; and (c) the subject matter and content of all discussions and meetings between the Parties regarding the subject matter of this Agreement, in each case, whether or not patentable or
copyrightable or subject to protection under applicable trade secret law. As used herein, “clinical test data” shall be deemed to include all information related to the clinical or preclinical testing of the Product, including patient
report forms, investigators’ reports, biostatistical, pharmaco-economic and other related analyses, regulatory filings and communications, and similar data, documentation and information. 

 

	 	13.	 “Intellectual Property” or “IP” means any and all intellectual property rights and similar
proprietary rights, including Patents, trademarks, copyrights and Information, whether registered or unregistered, and all applications and registrations to register, and renewals and extensions of, any of the foregoing in any jurisdiction.

  

	 	14.	 “JSC” means a joint steering committee. 

 

	 	15.	 “Licensee Party” means a Party to this Agreement is receiving from the other Party to the Agreement a
license to IP. 

  

	 	16.	 “Licensor Party” means a Party to this Agreement that is granting the other Party to this Agreement a
license to IP. 

  
 2 

	 	17.	 “Loss” means any payment, cost, damage, disbursement, expense, loss, liability, deficiency, lost
profit, diminution in value, interest, penalties, costs or expenses (including reasonable outside legal, accounting and other professional fees). 

  

	 	18.	 “MOA” means mechanism of action. 

 

	 	19.	 “NDA” means New Drug Application. 

 

	 	20.	 “Net Profits” means gross cash revenue actually received by NeuroRx or Relief, as applicable, for
sales of the Product, less all costs and expenses, direct and indirect, incurred or borne by or on behalf of NeuroRx or Relief, respectively, arising in connection with any such sales of the Product. These costs include (but are not limited to), for
example, all (i) normal and customary trade and quantity discounts, (ii) reasonable discounts, allowances, credits, chargebacks and refunds (e.g., for any nonconforming, damaged, rejected, outdated, returned, withdrawn or recalled
Product), (iii) rebates and price reductions and adjustments required by any applicable law or regulation or contract, (iv) sales, value added, excise and all other taxes and duties and any other governmental charges imposed upon the
importation or sale of the Product, (v) damages or other losses arising out of or resulting from Third Party claims, (vi) overhead, labor, equipment, warehousing, storage, logistics, freight and transport costs and expenses, and
(vii) royalties paid to third parties. In the case of any sale of the Product for consideration other than cash, such as barter or countertrade, Net Profits shall be calculated assuming the fair market value of the consideration received as
agreed by the Parties, each acting reasonably and in good faith. The foregoing definition and all financial definitions herein shall be determined in accordance with generally accepted accounting principles as applicable in the United States, or
similar accounting principles in Switzerland if applicable, as generally and consistently applied. 

  

	 	21.	 “NeuroRx Territory” means the U.S., Canada, and Israel (and, as applicable, all territories and
possessions of any of the foregoing). 

  

	 	22.	 “NIH” means the United States National Institutes of Health. 

 

	 	23.	 “Patents” means any patents and patent applications, together with all additions, divisionals,
continuations, continuations-in-part, substitutions, reissues, re-examinations, extensions, registrations, patent term
extensions, supplemental protection certificates and renewals of any of the foregoing, and all foreign counterparts thereof in any jurisdiction. 

  

	 	24.	 “Person” means and includes any individual, partnership, joint venture, limited liability company,
corporation, firm, trust, unincorporated organization and government or other department or agency thereof. 

  

	 	25.	 “Product” means aviptadil (also known as RLF-100 or a drug
name mutually agreed upon by the Parties and approved by the FDA) for any route of administration, including intravenous and inhaled use, as long as Relief funds the research and development costs for developing such use. Relief may use a different
brand name in the Relief Territory (as defined below). 

  
 3 

	 	26.	 “Regulatory Agency” means the FDA or any regulatory body with similar regulatory authority in the
United States or any jurisdiction outside the United States. 

  

	 	27.	 “Regulatory Exclusivity” means any exclusive marketing authority conveyed by a Regulatory Agency that
precludes generic competition. 

  

	 	28.	 “Regulatory License” means any marketing authority conveyed by a New Drug Approval, Emergency Use
Authorization, fast track approval, or their equivalents granted by a Regulatory Agency. 

  

	 	29.	 “Relief Territory” means the EU, Switzerland, Iceland, Norway, the UK, the Channel Islands,
Liechtenstein, Monaco, Andorra, Malta, San Marino, and Vatican City (and, as applicable, all territories and possessions of any of the foregoing). 

  

	 	30.	 “Revenues” means net sales, together with any other consideration or payments received in connection
with the present or future commercialization or licensing of the Product, including license and sublicense fees and milestone payments. 

  

	 	31.	 “ROW Countries” means all countries (and, as applicable, all territories and possessions of any of
the foregoing) other than those included in the NeuroRx Territory or the Relief Territory. 

  

	 	32.	 “Territory” means, in reference to Relief, the Relief Territory and, in reference to NeuroRx, the
NeuroRx Territory. 

  

	 	33.	 “Third Party” means any Person other than either Party or any of its respective Affiliates.

  

	 	34.	 “U.S.” and “United States” means the United States (including its territories and
possessions) and Puerto Rico. 

  

	 	35.	 “Weekly Call” means a recurring weekly call on a day and time to be mutually agreed to by the
Parties, the purpose of which will be for the Parties to discuss the Product, the Collaboration and other related matters. 

  

	2.	 Scope of Collaboration Between Relief and NeuroRx 

 

	 	2.1.	 NeuroRx and Relief agree that the execution of this Agreement grants each Party complete freedom to operate
under the other’s Intellectual Property pertaining to the Product in their respective Territories. Should additional documents be required in the future to perfect this provision, the Parties agree to promptly execute such documents. In the
event the Parties are unable to agree upon the terms and conditions of such documents, counsel to each Party shall jointly appoint an arbitrator who will prepare any required documents. 

  
 4 

	 	2.2.	 NeuroRx and Relief will collaborate to assist each other in maximizing sales and revenues from the Product in
their respective Territories. 

  

	 	2.3.	 NeuroRx will lead and have control over the U.S. clinical effort on the Product, subject to the terms set forth
herein; and NeuroRx will have control over commercialization of the Product in the NeuroRx Territory, subject to the terms set forth herein. Relief will have control over commercialization of the Product in the Relief Territory, subject to the terms
set forth herein. In the event that there exists a conflict between this Section 2.3 and any other provision in this Agreement, Section 2.3 shall control. 

 

	 	2.4.	 The Parties acknowledge and agree that the Collaboration will allow both Parties to better use their existing
assets than they would be able to absent the Collaboration. The Collaboration will enable the development and commercialization of the Product to treat COVID-19 faster and more efficiently than would be
possible absent the Collaboration. 

  

	3.	 Assets to be Utilized in the Collaboration 

 

	 	•	 	 Relief Assets to be utilized in the Collaboration include: 

 

	 	•	 	 Cash or cash equivalents required to continue providing sole funding of the Collaboration; 

 

	 	•	 	 Product drug substance; 

 

	 	•	 	 U.S. Patent No. 8,178,489, related Patents derived from U.S. Patent Application Serial No. 11/817,867
and foreign formulation Patents; 

  

	 	•	 	 U.S. and European Union Orphan Drug Designations related to ARDS, sarcoidosis, and pulmonary hypertension;

  

	 	•	 	 EU-compliant and possibly U.S.-compliant toxicity file and pre-clinical data; and 

  

	 	•	 	 Clinical Phase 2 data from prior in-human trials conducted in the EU:

  

	 	•	 	 Pulmonary fibrosis (failed); 

 

	 	•	 	 Pulmonary hypertension (failed); and 

 

	 	•	 	 Sarcoidosis (+ intermediate endpoint). 

 

	 	•	 	 NeuroRx Assets to be utilized in the Collaboration include: 

 

	 	•	 	 Regulatory Information; 

  
 5 

	 	•	 	 Existing U.S. corporation and expertise in U.S. corporate matters; 

 

	 	•	 	 Current authorized United States IND applications that may be used to intravenously deliver the Product in
critical COVID-19 cases; 

  

	 	•	 	 Current authorized United States IND for inhaled use of the Product in moderate and severe COVID-19 cases; 

  

	 	•	 	 GCP clinical trial structure with multiple qualified study sites, a Data Monitoring Committee, Advarra IRB,
active protocols, and substantial ongoing data collection; 

  

	 	•	 	 IBM Watson grant for transition to IBM Watson electronic data capture system; 

 

	 	•	 	 cGMP formulation and stability data for the Product, sterile product for intravenous and inhaled use;

  

	 	•	 	 Information regarding manufacturing techniques required to ensure potency of the Product; 

 

	 	•	 	 Ongoing relationship with Operation Warp Speed, NIH, BARDA, and State organizations and related documents,
correspondence, submissions and other materials pertaining thereto; 

  

	 	•	 	 Information included or embodied in United States IND 149,152 or United States IND 151,070 and related documents
filed, and correspondence and submissions with, the FDA and other materials pertaining thereto; 

  

	 	•	 	 Qualification through SAMS as a qualified USG entity; and 

 

	 	•	 	 Teaming agreements as a SAMS-qualified entity with the Henry Jackson Foundation, ICONgphs, and other BARDA
preferred partners. 

  

	4.	 Development Plan and Budget 

 

	 	4.1.	 NeuroRx shall direct, design and implement the entire pathway for U.S. drug approval for the Product (the
“Project”). 

  

	 	4.2.	 NeuroRx shall be the designated party to all contractual agreements related to the manufacture and marketing of
the Product in the NeuroRx Territory with external service providers and the sole named entity on all invoices related to activities associated with the Project. If Relief now or in the future chooses a commercialization partner other than NeuroRx
in the NeuroRx Territory pursuant to Section 8.11 hereof, NeuroRx will assign all contractual agreements and Regulatory Licenses to Relief’s chosen commercialization partner. 

  
 6 

	 	4.3.	 Relief shall be the designated party to all contractual agreements related to the manufacture and marketing of
the Product outside the NeuroRx Territory with external service providers and the sole named entity on all invoices related to activities associated with the pathway for marketing approval for the Product outside NeuroRx Territory.

  

	 	4.4.	 NeuroRx is responsible for ensuring that all activities undertaken under the Project (a) comply with the
Development Plan, (b) do not exceed 30% of the budget contemplated by Relief’s Board of Directors on March 22, 2020 (as may be amended by the written agreement of Relief and NeuroRx) and (c) comply with all applicable laws.

  

	 	4.5.	 Given that Relief is a 50% partner in Net Profits earned in the NeuroRx Territory, all individual employees
paid in excess of $500,000 shall be reasonably acceptable to Relief, such agreement not to be unreasonably withheld or delayed. 

  

	 	4.6.	 The Parties recognize that the March 22, 2020 budget did not contemplate the costs that have been incurred
for drug formulation, manufacture, CMC, stability, etc., which costs have been funded by Relief. 

  

	 	4.7.	 Material updates or changes to the Development Plan or the budget (i.e., increased costs in the aggregate which
exceed 30%) for the Project shall be approved by Relief’s Board of Directors, which shall not be unreasonably withheld or delayed. 

  

	 	4.8.	 Each of NeuroRx and Relief shall refrain from contacting any representative of any service provider, supplier
or vendor in the NeuroRx Territory, in the case of Relief, and in the Relief Territory, in the case of NeuroRx, engaged or otherwise involved in the Project (including any and all service providers, suppliers and vendors involved in the performance
of clinical development activities associated with the Product) in a manner that is reasonably likely to have a material and adverse effect on the Project without providing the other Party with reasonable prior written notice and the opportunity to
participate in discussions and negotiations therewith; provided that NeuroRx shall not be obligated to provide such advance notice or opportunity to participate to Relief solely to the extent such contact is imminently necessary to provide patient
care and provided that NeuroRx provides notice to Relief of such contact immediately thereafter. 

  

	 	4.9.	 Revenues from grants, Priority Review Vouchers, or any other similar sources, shall be divided between the
Parties as follows: in the NeuroRx Territory 50/50 and in the Relief Territory 85/15, and on an 80/20 basis in Relief’s favor in the ROW Countries. 

  

	5.	 Exclusivity and Cooperation 

 

	 	5.1.	 Unless otherwise provided herein, each of NeuroRx and Relief shall refrain from, and shall use commercially
reasonable efforts to cause its Affiliates to refrain from, directly or indirectly (which for the avoidance of doubt shall include via any Person that is an equity holder of any of the foregoing) engaging in any development activities for, or
conducting any unilateral bids to identify or solicit bids from contract manufacturers to synthesize or formulate, any drug or any related substance, product or treatment intended to be used to treat, combat, ameliorate, prevent or mitigate the
effects of COVID-19 or any ailment reasonably related thereto that does or could reasonably be expected to compete against or reduce sales (or other monetization) of the Product. To the extent NeuroRx or any
of its Affiliates controls any Third Party that are related to the Product or the development of the Product, this restriction shall also apply to each such Third Party. 

  
 7 

	 	5.2.	 It is acknowledged and agreed that each Party retains the right to develop and own IP that is not related to
the Collaboration in any way, and Relief retains the freedom to operate and in-license the development of treatments for indications other than COVID-19 that use the
same or a different MOA than the Product. 

  

	 	5.3.	 Relief may elect to fund all expenses associated with RLF-100 and/or
related molecules in areas outside COVID-19. Should Relief elect to do so, NeuroRx will have the option to participate in the clinical and regulatory development of the drug and/or related molecules in those
areas, but if it does not exercise its option to participate (i.e., within 30 days of receipt of written notice by Relief of its initiation of development programs in those areas), then Relief shall be entitled to select a different development
partner or conduct the work itself, without further obligation to NeuroRx with respect to future sales of the drug and/or related molecules in those indications. NeuroRx shall receive an opt-in right if it is
involved with the clinical and regulatory development of the drug and/or related molecules in these non-COVID-19 indications, and if NeuroRx exercises such an opt-in right for those indications in its Territories (namely, the United States, Israel and Canada), it shall be entitled to 50% of the Net Profits in those areas if it commercializes the drug and/or related
molecules for those indications. If NeuroRx does not exercise its opt-in right (i.e., within 30 days of written notice by Relief of the release of positive clinical data from those studies), then it shall not
be entitled to any revenue split whatsoever. Relief shall own all rights to all Revenues and Net Profits in areas outside the NeuroRx Territory and shall fund and conduct all development, regulatory and commercial costs in those areas.

  

	 	5.4.	 If NeuroRx or any of its Affiliates seeks to develop itself or collaborate with another Person on any treatment
for acute respiratory distress syndrome, acute lung injury, asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, sarcoidosis, and influenza, regardless of MOA, which, in each case, is
non-COVID related, then: (a) if Relief provides all funding, it shall be entitled to 50% of NeuroRx’s Net Profits, and (b) if Relief does not provide all funding, it shall be entitled to 2.5% of
NeuroRx’s Net Profits. 

  

	 	5.5.	 Each of NeuroRx and Relief agree to work cooperatively to enhance the value of the Product through the pursuit
of business development initiatives, including solicitation of partnership or distribution arrangements aimed at facilitating the advancement and commercialization of the Product. Both Parties shall make every effort to ensure that such
solicitations can be advanced in a timely manner, including execution of non-disclosure or confidentiality agreements and sharing of necessary information with prospective partners. 

  
 8 

	 	5.6.	 Each Party shall, as promptly as reasonably practicable, inform the other Party and regularly report its
business development activities that pertain to this Agreement and the Product to the other Party. Without limiting the generality of the foregoing, representatives from the Parties, including Dr. Javitt and Aaron Gorovitz on behalf of NeuroRx,
will attend the Weekly Calls to report all updates on the Product and the Collaboration to Relief. 

  

	 	5.7.	 Any material licensing, partnership or distribution or other similar agreement proposed by a Third Party entity
with respect to the Product shall be subject to express prior written consent of each Party (such consent not to be unreasonably withheld or delayed). 

  

	 	5.8.	 Each of the Parties shall refrain from, and shall use commercially reasonable efforts to cause its Affiliates
to refrain from, taking any action, or permitting any Person from taking any action that could frustrate the exclusivity provisions set forth above. 

  

	6.	 Invoices and Audit Right 

 

	 	6.1.	 NeuroRx shall, as promptly as reasonably practicable, provide accurate and complete vendor and other service
provider invoices, along with supporting documentation and any other information reasonably requested by Relief, and Relief shall pay such invoices in accordance with the approved budget for the Project and the terms of the applicable vendor or
service provider contract. 

  

	 	6.2.	 Within 15 business days of the effectiveness of this Agreement, NeuroRx shall provide to Relief all invoices,
purchase orders, receipts, contracts (both written as well as a description of the material terms of any oral agreements that are legally binding), and expense documentation for any costs incurred with respect to its Product development activities
through such date. 

  

	 	6.3.	 Relief shall have customary and reasonable rights to access all books and financial records of NeuroRx and its
Affiliates with respect to the Project. 

  

	 	6.4.	 If and to the extent approved by the applicable Third Party contractors, Relief shall also have customary and
reasonable rights to access relevant records of material Third Party contractors engaged by NeuroRx or any of its Affiliates with respect to the Project, and NeuroRx shall cooperate with Relief with respect to Relief’s obtaining such records.

  
 9 

	7.	 Press Releases and Material Information 

 

	 	7.1.	 None of NeuroRx, Relief, any of its respective Affiliates or any Person acting at the direction or on behalf of
NeuroRx, Relief or any of its respective Affiliates, shall issue any press releases or public statements pertaining to the Collaboration, the Project, the Product or any related activities or subject matter without prior express written consent of
the other Party, except as required by applicable laws in which case the issuing Party or Person shall provide the other Party with reasonable prior written notice thereof. All press releases regarding the Product shall be issued in accordance with
all applicable laws. The Parties recognize that press interviews will be given by both Parties, and a set of talking points regarding the Collaboration, the Project, the Product and any related activities or subject matter will be prepared at the
Weekly Calls, approved by NeuroRx and Relief, and provided to each Party. Each Party shall adhere, and shall require its Affiliates and other Third Parties acting on such Party’s or its Affiliates’ behalf to adhere, to such talking points.

  

	 	7.2.	 In part due to the fact that Relief is publicly listed in Switzerland and regulated by the Swiss Stock Exchange
(SIX), NeuroRx commits to coordinate and cooperate with Relief regarding the timely public release of all material information pertaining to the development and commercialization of the Product. Such information will be discussed on the Weekly
Calls, and more frequently as may be necessary to comply with Relief’s obligations. This clause shall be deemed to refer to, but shall not be construed to obligate the release of, scientific or other similar documents, materials, date or
information, before its primary authors consider the foregoing appropriate for public release. 

  

	 	7.3.	 During the Weekly Calls, or more frequently as necessary or reasonably requested by Relief, NeuroRx shall
provide progress reports and status updates to Relief regarding the RLF-100 development program, including ongoing updates regarding all current and planned clinical trials, clinical activity profile of the
Product, technical specifications, stability data, and any other information that pertains to the composition and formulation of the Product in any of its manifestations. Any and all drug-related serious adverse events as defined by the FDA shall be
transmitted by NeuroRx to Relief in a timely manner, and in no event less frequently or later than the Weekly Calls. 

  

	 	7.4.	 NeuroRx shall promptly furnish to Relief, subject to approval, if needed, by applicable licensors in license
agreements to which NeuroRx is licensee, any and all information in its possession, including IND filings owned or licensed by NeuroRx, that is not currently in the public domain pertaining to (i) the clinical activity profile of the Product,
(ii) technical specifications, (iii) stability data, (iv) the composition and formulation of the Product in any of its manifestations, and (v) any financing arrangement that reasonably relates to the Product or Collaboration,
including any such financing with any Prior Funding Source (defined below). 

  

	 	7.5.	 Within three business days of the effective date of this Agreement (or earlier if required by any applicable
law or securities exchange regulations), the Parties shall jointly release an agreed upon press release that indicates what each Party brought to the Collaboration and how the Parties intend to move forward with the Collaboration. In the event that
the Parties are unable to mutually agree on any such joint press release, counsel for each Party shall agree on and appoint a mediator who will decide the issue within 3 days. 

  
 10 

	8.	 Consideration 

 

	 	8.1.	 Relief shall fund the estimated $8.3 million clinical trial budget as approved by Relief’s Board of
Directors on March 22, 2020 and as may be amended by the written agreement of Relief and NeuroRx. It is understood that clinical research budgets are estimates only because one can never know exactly how many patients will be enrolled, what
actual medical costs will be, how many hours will be spent on statistics, report-writing, etc. That being said, any amended budget shall be subject to prior approval by Relief and NeuroRx and shall provide for reasonable cost overruns based on
changes in the regulatory environment and requirements. Budget overages of less than 30% shall be automatically approved. In the event that Relief does not approve additional overages, NeuroRx shall be free to bring in other Persons in order to
complete the Project. 

  

	 	8.2.	 Relief shall fund the costs of formulation and stability of the Product at MediSourceRx and Bachem, together
with technology transfer to Nephron Pharmaceuticals or other mutually agreeable commercial manufacturers. 

  

	 	8.3.	 Relief shall fund the documented costs of purchasing drug substance from Bachem and manufacturing drug product
at MediSourceRx and Nephron Pharmaceuticals. 

  

	 	8.4.	 Relief shall be reimbursed for all costs of goods sold paid for by Relief prior to calculating any Net Profit
sharing by the Parties in any Territory as set forth in this Agreement. 

  

	 	8.5.	 Each Party will develop a Commercialization Plan for the Product for such Party’s respective Territory
mutually agreed upon by the other Party (such agreement not to be unreasonably withheld, conditioned or delayed) within 60 days hereof. In the event that the Parties are unable to mutually agree on any such Commercialization Plan, counsel for each
Party shall jointly appoint an arbitrator who will decide the issue in binding arbitration within 14 days. 

  

	 	8.6.	 If there is a dispute regarding either Party’s Commercialization Plan, the Parties will engage a mutually
agreed arbiter, and any costs with respect to such engagement shall be shared on a 50/50 basis by the Parties. 

  

	 	8.7.	 Each Party will use “commercially reasonable efforts” to commercialize Product in its respective
Territory consistent with its Commercialization Plan. 

  

	 	8.8.	 Each of NeuroRx and Relief can audit the distributor as needed. Final decisions regarding the distribution
partner in the NeuroRx territory shall be made by NeuroRx, and final decisions regarding the distribution partner for the Relief Territory shall be made by Relief. 

 

	 	8.9.	 Each Party will provide access and right of reference to all existing clinical,
non-clinical, and CMC information for the Product that it owns or licenses from a Third Party. 

  
 11 

	 	8.10.	 Each Party will have full rights to commercialize the Product in its respective Territory, in each case,
subject to its Commercialization Plan including, e.g., the right to commercialize Product in its respective Territory itself or through any licensees, distributors or other Third Parties and with the right to contract with contract research
organizations, contract marketing organizations and other Third Parties. Each Party agrees not to commercialize the Product in the other Party’s Territory. 

 

	 	8.11.	 The Parties acknowledge that the efficacy of RLF-100 is currently
unknown and the commercial sales model will be driven by the efficacy-driven label together with the available patient population. Entry of vaccines and other therapeutics could dramatically alter the incidence of Critical COVID-19 with Respiratory Failure as can the overall incidence of SARS-CoV-2 infection. For this reason the Parties have agreed to
engage IQVIA to build a commercial sales model based on the Target Product Profile that is informed by interviews with physicians, payers, and hospitals. This model will yield a target price point and potential market penetration. The actual sales
target will be adjusted up or down by changes in the actual infection rate as reported by the CDC. NeuroRx will commit to a standard peak sales penetration model together with Relief, which is typically 20%/40%/60%/80%/100% of forecast peak sales in
years 1-5 respectively. Should NeuroRx underperform its target by 30% or more without macroscopic changes in the market environment, Relief shall have the right to demand an outside sales entity be engaged to
manage US sales. 

  

	9.	 Profit Sharing 

 

	 	9.1.	 NeuroRx shall receive 50% of Net Profits and Relief shall receive 50% of Net Profits from the Product sales in
the NeuroRx Territory. NeuroRx shall maintain books and records sufficient to confirm the Net Profits generated from the sales of Product in the NeuroRx Territory consistent with GAAP. Relief will have the right (itself or through an independent
auditor) to audit NeuroRx’s books and records to confirm the Net Profits from NeuroRx’s sales of Product in the NeuroRx Territory. 

  

	 	9.2.	 NeuroRx shall receive 15% of Net Profits and Relief shall receive 85% of Net Profits from the Product sales in
the Relief Territory. Relief shall maintain books and records sufficient to confirm the Net Profits generated from the sales of Product in the Relief Territory consistent with GAAP. NeuroRx shall have the right (itself or through an independent
auditor) to audit Relief’s books and records to confirm the Net Profits from Relief’s sales of Product in the Relief Territory. Should Relief request assistance from NeuroRx in clinical development, manufacture, or commercialization,
NeuroRx shall be entitled to additional consideration as agreed between the Parties. 

  

	 	9.3.	 NeuroRx shall receive 20% of Net Profits and Relief shall receive 80% of Net Profits from the Product sales in
the ROW Countries. Relief shall maintain books and records sufficient to confirm the Net Profits generated from the sales of Product in the ROW Countries consistent with GAAP. NeuroRx shall have the right (itself or through an independent auditor)
to audit Relief’s books and records to confirm the Net Profits from Relief’s sales of Product in the ROW Countries. Should Relief request assistance from NeuroRx in clinical development, manufacture, or commercialization, NeuroRx shall be
entitled to additional consideration as agreed between the Parties. 

  
 12 

	10.	 Intellectual Property and Regulatory Approvals 

 

	 	10.1.	 Each Party shall appoint a law firm acceptable to the other to manage the filing of applications and the
prosecution thereof and the ownership (which may not necessarily follow inventorship), protection, maintenance, enforcement, and defense of Patents, trademarks and other IP in their respective Territories and, as applicable, any ROW Countries, other
customary IP provisions, and any other provisions mutually agreed upon by the Parties. Relief agrees that the firm appointed by NeuroRx may be Kirkland & Ellis, LLP. 

 

	 	10.2.	 Following the date hereof NeuroRx and Relief shall disclose to one another all IP owned, licensed, or claimed
by each in order to permit the parties to implement all cross-licensing or other arrangement involving ownership and licensing of IP between the Parties, subject to approval, if needed, by applicable licensors in license agreements.

  

	 	10.3.	 Relief agrees NeuroRx shall be designated as the sole applicant on any NDA or other application for a
Regulatory License submitted to FDA with respect to the Product. The Parties agree that Relief shall jointly control all material decisions related to the NDA or other application for a Regulatory License and related matters and receive half the
economic benefit of all NDAs or other Regulatory Licenses and related IP and commercialization thereof in the United States. 

  

	 	10.4.	 All IP, including all Patents or Information, that is related to the Collaboration or the Product and
(a) is or was created, developed, invented, made or enhanced by NeuroRx, any of its Affiliates, Dr. Javitt, or any Third Party vendor or service provider for or on behalf of NeuroRx, any of its Affiliates or Dr. Javitt, (b) is
owned or licensed by NeuroRx, any of its Affiliates or Dr. Javitt, or (c) the creation, development, invention, making or enhancement of which was funded in any manner by Relief (all such IP, “Prior IP”) is set forth on Schedule
A hereto. 

  

	 	10.5.	 Each of NeuroRx (on behalf of itself and its Affiliates) and Dr. Javitt shall, and shall use commercially
reasonable efforts to cause each of its respective Affiliates, vendors and service providers, as applicable, to, irrevocably crosslicense to Relief for use in its territory all of their respective right, title and interest in, to and under the Prior
IP (and shall abandon or assign to Relief the US trademark application for “RLF-100” after signing this Agreement), and each of NeuroRx and Dr. Javitt shall take, and shall use commercially
reasonable efforts to cause each of its respective Affiliates, vendors and service providers, as applicable, to take, all necessary actions to obtain, effectuate and perfect such assignments. 

  
 13 

	 	10.6.	 Relief (on behalf of itself and its Affiliates) hereby, and shall promptly cause each of its respective
Affiliates, vendors and service providers, as applicable, to, irrevocably crosslicense to NeuroRx for use in its territory all of their respective right, title and interest in, to and under the Prior IP, and Relief shall take, and shall promptly
cause each of its respective Affiliates, vendors and service providers, as applicable, to take, all necessary actions to obtain, effectuate and perfect such assignments. 

 

	 	10.7.	 Intellectual Property that is developed jointly by the Parties relating to the Product during the term of this
Agreement will be owned jointly by the Parties in accordance with US patent law (“Joint IP”). To be considered Joint IP, the subject Intellectual Property shall be invented by at least one employee, contractor or agent of each Party (each,
a “Party Inventor”) working collaboratively with one another regardless of the location(s) in which the respective Party Inventors conduct the inventive activities that contribute to the invention of the Joint IP. Relief will assign to
NeuroRx its rights in such Joint IP in the NeuroRx Territory, and NeuroRx will assign to Relief its rights in such Joint IP in the Relief Territory. The Parties will ensure that the rights to Joint IP necessary to ensure freedom to operate for each
Party in the ROW Countries are cross-licensed in the license grants contemplated in this Section 10. 

  

	 	10.8.	 All publications and manuscripts, whether published or submitted or proposed for publication, related to the
Product and authored by Dr. Javitt or any employee, consultant or contractor of NeuroRx, any of its Affiliates or Dr. Javitt as of the effective date of this Agreement (“Prior Publications”) are set forth on Schedule B hereto.

  

	 	10.9.	 All sources, aside from Relief, that have provided or agreed to provide any capital, funding, grants, or
financial support in any form to Dr. Javitt or NeuroRx to be used in connection with, or to in any manner further, the Collaboration or any element thereof., and the amounts provided, as of the effective date of this Agreement (“Prior
Funding Sources”) are set forth on Schedule C hereto. Prior to the date hereof, NeuroRx has provided Relief with all documentation related to any financing or other related matters with each Prior Funding Source. 

 

	11.	 Representations and Warranties 

Each of the Parties hereby represents and warrants to the other Party, as of the date hereof, as follows: 

 

	 	•	 	 Such Party is duly organized or incorporated (as the case may be), validly existing and in good standing under
the jurisdiction of its incorporation or organization, has all requisite power and authority to carry on its business as now conducted, has full power and authority to enter into this Agreement, consummate the transactions contemplated hereby and to
perform its obligations hereunder. 

  
 14 

	 	•	 	 The execution, delivery and performance by such Party and the consummation of the transactions contemplated
hereby: 

  

	 	•	 	 (a) have been duly and validly authorized and approved by the board of directors of such Party, and no other
corporate actions or proceedings on the part thereof is necessary to authorize this Agreement and the transactions contemplated hereby; 

  

	 	•	 	 (b) to the best of such Party’s knowledge, do not and will not result in the creation or imposition of
any liens with respect to any of the material assets or properties of such Party; and 

  

	 	•	 	 (c) to the best of such Party’s knowledge, do not and will not result in a violation or breach of or
conflict with (i) such Party’s articles, bylaws, or other organizational documents, (ii) any law, rule, regulation or order to which such Party is subject, or (iii) any judgment, order, or decree of any governmental authority to
which such Party is subject, or otherwise result in a violation or breach of or conflict with, or constitute a default under, or result in the acceleration of any material provision of, any contract or agreement to which such Party is bound.

  

	 	•	 	 The provisions set forth in this Agreement constitute legal, valid and binding obligations of such Party
enforceable against such Party in accordance with their respective terms, except to the extent that enforceability may be limited by applicable bankruptcy, insolvency or similar laws affecting the enforcement of creditors’ rights generally and
subject to general principles of equity (regardless of whether such enforcement is considered in a proceeding at law or at equity), public policy or national security. 

 

	 	•	 	 Such Party is in material compliance with all applicable laws, regulations, rules and orders and there is no
basis that, with or without notice or the passage of time (or both), would, individually or in the aggregate, be reasonably expected to constitute or give rise to a violation of, any applicable law, regulation, rule or order. 

 

	 	•	 	 There are no actions pending against or affecting such Party’s ability to enter into or complete its
obligations under this Agreement. 

  

	 	•	 	 Neither this Agreement (including the Schedules hereto) nor any other documents, certificates or instruments
furnished by a Party to the other Party its Affiliates in connection with the Collaboration contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made herein or therein, in the
light of the circumstances under which they were made herein or therein, not misleading. 

  

	 	•	 	 Notwithstanding the foregoing, each Party, on its own behalf and on behalf of its respective Affiliates,
acknowledges and agrees that (a) such Party’s representations and warranties set forth herein constitute the sole and exclusive representations and warranties of such Party in connection with the Agreement and the transactions contemplated
hereunder; (ii) neither such Party, nor any of its representatives or Affiliates, nor any other Person makes, or has made, any other express or implied representation or warranty with respect to the Agreement or the transactions contemplated
hereunder; and (iii) each Party is relying solely upon the other Party’s representations and warranties hereunder and are not relying, and have not relied, upon any other information, document or material provided to or made available to
such Party, or any of its representatives or Affiliates (including the completeness or accuracy thereof), whether oral or written, delivered to or made available prior to or after the date hereof. 

  
 15 

	12.	 Other Terms 

 

	 	12.1.	 The Parties recognize that the Product – a form of vasoactive intestinal peptide (VIP) – is a generic
product, sold by multiple drug substance suppliers in multiple countries, and is currently listed in the FDA “Bulks” list for sale by any compounding pharmacy. The Parties further recognize that: 

 

	 	•	 	 Relief owns U.S. Patent No. 8,178,489 and related patents derived from U.S. Patent Appl. Serial
No. 11/817,867 and its international counterparts that cover certain formulations of the Product but does not cover either its use or composition of matter; 

 

	 	•	 	 it would be in their mutual interest for Relief to obtain additional IP and a patent term extension related to
the Product; 

  

	 	•	 	 Relief has certain Information that may be useful in commercializing the Product; and 

 

	 	•	 	 NeuroRx has Information, included or embodied in United States IND 149,152, 151,070 and related documents filed
with the FDA. 

  

	 	12.2.	 NeuroRx’s Commercialization Plan for the NeuroRx Territory shall (i) include a branding plan, sales
team information, pricing and market research, documentation of advanced purchase orders, forward contracts, bulk supply arrangements, distribution arrangements, and other topics customary for the commercialization of a pharmaceutical product in the
United States. NeuroRx will choose a name, with Relief’s consultation that meets FDA approval. For the avoidance of doubt, Relief shall have sole right to identify commercialization partners everywhere in the world other than the NeuroRx
Territory, which shall be subject to the terms of this Agreement. Both Relief and NeuroRx agree that this process shall be mediated by a Person with recognized expertise in pharmaceutical industry asset licensing or acquisition.

  

	 	12.3.	 If either Relief or NeuroRx wants to expand the Product franchise outside the scope of the Collaboration in its
respective Territory, it shall be entitled to keep 100% of the Revenues. Neither party may expand into the other’s Territory without the other’s permission 

  
 16 

	 	12.4.	 NeuroRx and Relief shall each maintain clinical trials insurance that covers all subjects enrolled in clinical
development activities conducted by the respective Party. 

  

	 	12.5.	 Relief agrees that it shall fund the costs associated with the clinical development of the inhaled Product in
the United States in reliance upon NeuroRx’s agreement to conduct, manage, supervise and oversee said clinical development. Should Relief not fund the clinical development costs, NeuroRx shall have the freedom to bring a replacement investor.

  

	 	12.6.	 The Parties will form a JSC to coordinate the activities between the Parties with regard to each Party’s
respective Territory. The JSC shall not have governing authority, and will be limited to an advisory capacity and will not have any governing or decision-making authority. The main role of the JSC is to ensure that neither Party undertakes
regulatory actions that could adversely affect the other Party (e.g., failure to report adverse events and other issues that arise in the Parties’ respective Territories that would reasonably be likely to impact the other Party or the Product.
For clarity, each Party will have the right to have final say with regard to its own respective Territory. 

  

	13.	 Choice of Law, Venue, Dispute Resolution, and Miscellaneous 

 

	 	13.1.	 Any disputes arising from this Agreement shall be addressed first by escalating to senior executives of each
Party for resolution over the course of a period of 30 days (or another mutually agreed period of time) except with regards to disputes over alleged or possible violations of law or public policy or involving matters of national security.

 This Agreement and all questions regarding its validity or interpretation, or the performance or breach of this
Agreement, shall be governed by and construed and enforced in accordance with the laws of New York, without reference to conflicts of laws principles. Venue shall be in the courts of New York. Each Party hereby irrevocably submits to the exclusive
jurisdiction of the courts of New York. 
  

	 	13.2.	 The section headings in this Agreement are included only for convenience of reference and shall not in any way
affect the construction of, or be taken into consideration in interpreting, this Agreement. In this Agreement: (a) the word “including” shall be deemed to be followed by the phrase “without limitation” or like expression;
(b) the words “Subject to further discussion between the Parties”, “mutually agreed to by the Parties” or words of other similar import, shall each be deemed to be followed by the phrase “each of the Parties acting
reasonably and in good faith, consistent with the principles set forth in this Agreement”, (c) the word “commercialization” shall be deemed to also reflect the words “or other monetization”, (d) references to the singular
shall include the plural and vice versa; (e) references to masculine, feminine and neuter pronouns and expressions shall be interchangeable; and (f) the words “herein” or “hereunder” relate to this Agreement. If any
term or other provision of this Agreement is determined by a court of competent jurisdiction to be invalid, illegal or incapable of being enforced by any rule of law or public policy, all other terms, provisions and conditions of this Agreement
shall nevertheless remain in full force and effect. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the
original intent of the Parties as closely as possible to the fullest extent permitted by applicable law in an acceptable manner to the end that the Collaboration is fulfilled to the extent possible. 

  
 17 

	 	13.3.	 This Agreement will be publicly disclosed by the parties as required by law, with the prior written consent of
the parties. Specifically, this Agreement may be disclosed (a) to potential future investors who sign a nondisclosure agreement and (b) if required in connection with NeuroRx going public or merging with a public company and in connection
with required public filings of Relief. The Parties agree that this Agreement constitutes a binding legal obligation of the Parties; provided that if the Parties fail to receive any approvals, clearances or other permission necessary to proceed with
respect to the Collaboration contemplated herein, the Parties will make the necessary amendments hereto to obtain approvals. 

  

	 	13.4.	 No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of
an amendment, by both Parties; or, in the case of a waiver, by the Party against whom enforcement of any such waiver is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be
a continuing waiver in the future or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either Party to exercise any right hereunder in any manner impair the exercise of any such right accruing to it
thereafter. This Agreement contains the entire agreement between the Parties with respect to the subject matter hereof, and supersedes any and all prior understandings or agreements, whether written or oral, and there no promises, agreements,
conditions, undertakings, warranties, or representations (whether oral or written, express or implied) between them other than as herein set forth. Neither Party shall assign or transfer this Agreement or any of its rights or obligations hereunder,
in whole or in part, without the prior written consent of the other Party; provided that either Party may assign or transfer this Agreement or any or all of its rights or obligations under this Agreement from time to time without consent:
(a) to an Affiliate; or (b) to an acquirer of all or substantially all of such Party’s business, equity or assets. This Agreement shall be binding upon and inure to the benefit of the Parties and their successors and permitted
assigns. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. There are no third party beneficiaries to this Agreement and nothing
contained in this Agreement is intended to or shall be interpreted to create any third party beneficiary claims. Each of the Parties hereto has jointly participated in the negotiation and drafting of this Agreement. In the event an ambiguity or a
question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by each of the Parties hereto and no presumptions or burdens of proof shall arise favoring any Party by virtue of the authorship of any provisions
of this Agreement. 

  
 18 

 13.5. Each Party represents to the other that (i) it is not aware of any facts which
would give rise to a cause of action related to the prior activities between the Parties and the COVID-19 drug, and (ii) it has no claims against the other based on facts which are known. 

13.6. Any costs with respect to binding arbitration or mediation shall be shared on a 50/50 basis by the Parties. 

[signature page follows] 

  
 19 

 Acknowledged and Agreed: 
  

	
	/s/ Raghuram Selvaraju
	Relief Therapeutics Holding AG
	By: Raghuram Selvaraju, Ph.D.
	Chairman of the Board

  

	
	/s/ Peter de Svastich
	Therametrics Discovery AG
	By: Peter de Svastich
	Director

  

	
	/s/ Jonathan C. Javitt
	NeuroKx, Inc.
	By: Jonathan C. Javitt, M.D., M.P.H.
	Chairman and CEO

 Date: September 18, 2020 

  
 20 

 SCHEDULE A – PRIOR IP 

US Trademark Application No. 88875871, “SAMIVIP”, filed April 17, 2020 

US Trademark Application No. 90087709, “SAMIVIR”, filed August 2, 2020 

US Trademark Application No. 90110838, “RLF-100”, filed August 13, 2020 

US Trademark Application No. 90179858, “SAMIAIR”, filed September 14, 2020 

US Provisional Patent Application entitled “Compositions and Methods for Treating COPD and Other Pulmonary Disorders Using Vasoactive Intestinal
Peptide” (currently in draft) 
 US Provisional Patent Application entitled “Compositions and Methods for Improving Quality of Life in Critical
Care Patients Using Vasoactive Intestinal Peptide” (currently in draft) 
 US Provisional Patent Application entitled “Direct Central Nervous
System Delivery of Vasoactive Intestinal Peptide for Treatment and Prevention of Neurological Disorders” (currently in draft) 
 Know-how relating to formulation, storage and intravenous delivery of Vasoactive Intestinal Peptide (aviptadil) 
 Know-how relating to formulation, storage and inhalation delivery of Vasoactive Intestinal Peptide (aviptadil) 

 SCHEDULE B – PRIOR PUBLICATIONS 

1. Youssef, Jihad G. and Al-Saadi, Mukthar and Zahiruddin, Faisal and Beshay, Sarah and Bitar, Mohammad and Javitt,
Jonathan, Rapid Recovery from COVID-19 Respiratory Failure with Comorbidity in 21 Patients Treated with Vasoactive Intestinal Peptide. THELANCET-D-20-16032, Available at SSRN: https://ssrn.com/abstract=3679909 
 2. Javitt, Jonathan and
Youssef, Jihad G., VIP: A COVID-19 Therapeutic that Blocks Coronavirus Replication (August 9, 2020). Available at SSRN: https://ssrn.com/abstract=3670129 

3. Youssef, Jihad G. and Said, Sami and Youssef, George and Javitt, Matthew J. and Javitt, Jonathan, Treatment of Sepsis-related Acute Respiratory Distress
Syndrome with Vasoactive Intestinal Peptide (July 29, 2020). Available at SSRN: https://ssrn.com/abstract=3662952 or http://dx.doi.org/10.2139/ssrn.3662952 

Note: These publications may be elsewhere on the internet in earlier forms 

 SCHEDULE C – PRIOR FUNDING SOURCES 

NeuroRx, Inc.EX-10.5

 Exhibit 10.5 

Execution Version 
 CERTAIN CONFIDENTIAL
INFORMATION INDICATED BY “[***]” HAS BEEN OMITTED FROM THE FILED COPY OF THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED 

COLLABORATION AND LICENSE AGREEMENT 

This COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into on March 19, 2021 (the “Effective
Date”) between ACER THERAPEUTICS INC., a Delaware corporation, with its principal place of business at 300 Washington Street, Suite 351, Newton, MA, USA (“Acer”), and RELIEF THERAPEUTICS HOLDING AG, a company
organized and existing under the laws of Switzerland and having its registered address at Avenue de Secheron 15, 1202 Geneve, Switzerland (“Relief”). Relief and Acer are sometimes referred to herein individually as a
“Party” and collectively as the “Parties.” 
 RECITALS 

WHEREAS, Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare
and life-threatening diseases; 
 WHEREAS, Acer owns or Controls certain Know-How, patents,
technology, documentation, data, and other materials related to Product (as defined herein); 
 WHEREAS, Acer and Relief entered into
that certain Option Agreement dated January 25, 2021 (the “Option Agreement”) whereby Acer granted, and Relief received, an option for an exclusive license under Acer’s relevant intellectual property rights (the
“Option”) with respect to Product in the Relief Territory (as defined herein); 
 WHEREAS, Relief desires to
exercise the Option and the Parties wish to establish a collaboration for Development (as defined herein) and Commercialization (as defined herein) throughout the world, all on the terms and conditions set forth herein. 

NOW THEREFORE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this
Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 

ARTICLE 1DEFINITIONS 
 As
used in this Agreement, the following initially capitalized terms, whether used in the singular or plural form, will have the meanings set forth in this Article 1. 

1.1. “Acer” has the meaning set forth in the preamble. 

1.2. “Acer Indemnitees” has the meaning set forth in Section 7.1. 

1.3. “Acer Know-How” means all unpatented inventions, technology, methods,
materials (including biological and pharmaceutical materials), Know-How, studies, pre-clinical and clinical data (including toxicology, safety data, and bioequivalence
studies), tests and assays, reports, manufacturing processes (including manufacturing batch records to support regulatory approvals), regulatory filings (including drafts) and approvals and other information Controlled by Acer, in each case that
relate to Product or the subject matter claimed in the Patent Rights. 

  
 1 

 1.4. “Acer Patents” means (a) the patents and patent
applications set forth in Exhibit A, (b) any other patents and patent applications Controlled by Acer during the Term that Cover Product, except that this clause (b) shall apply, for purposes of the Acer Technology License, solely
to the extent that Relief bears the responsibility and liability in respect of the Relief Territory for any royalties and other payments (including any upfront fees and milestone payments) to any Third Parties with respect thereto, and (c) any
reissue, divisional, continuation, reexamination, renewal, extension or supplementary protection certificate for each of the foregoing patents and patent applications either now pending or pending in the future, including all foreign and
international counterparts and related patents and patent applications either now pending or pending in the future. 
 1.5.
“Acer Product” means the specific Product described in Schedule 1.5. 
 1.6. “Acer
Sublicense” has the meaning set forth in Section 9.2(b). 
 1.7. “Acer
Technology” means the Acer Know-How, the Acer Patents and the BCM Patents. 
 1.8.
“Acer Technology License” has the meaning set forth in Section 9.2(a). 
 1.9.
“Acer Territory” means the U.S., Canada, Brazil, Turkey and Japan. 
 1.10. “Allocable Overhead”
means, as to Product in the Acer Territory, costs incurred by Acer or for its account which are attributable to Acer’s supervisory services and occupancy costs as well as its payroll, information systems, human relations or purchasing
functions. Allocable Overhead will not include any costs attributable to general corporate activities including, but not limited to and by way of example, executive management, investor relations, business development, legal affairs and finance. For
avoidance of doubt, costs deemed Allocable Overhead under this Agreement shall only be included once under a particular category (e.g., Cost of Goods Sold, Development Costs, Distribution Costs, Fully Burdened Manufacturing Cost, Marketing Costs and
Sales Costs). 
 1.11. “Affiliate” means, with respect to a Party, any corporation, firm, partnership or other
entity which directly or indirectly controls or is controlled by or is under common control with such Party. For the purpose of this definition, “control” (including, with correlative meaning, the terms “controlled by” and
“under the common control”) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such entity, whether by the ownership of more than
fifty percent (50%) of the voting stocking of such entity, by contract or otherwise. 
 1.12. “Agreement” has the
meaning set forth in the preamble. 

  
 2 

 1.13. “Applicable Laws” means the applicable provisions of any and
all national, supranational, regional, state and local laws, treaties, statutes, rules, regulations, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, permits (including Regulatory Approvals) of or from
any court, arbitration panel, Regulatory Authority, governmental agency or any authority having jurisdiction over or related to subject item or subject person, including laws regulating pharmaceutical products, GCP, GMP, the FCPA, Export Control
Laws and other applicable laws. 
 1.14. “BCM License” means, collectively, the Exclusive License Agreement
effective as of April 4, 2014, by and between Baylor College of Medicine (“BCM”) and Acer, as amended by the First Amendment to License Agreement effective as of April 28, 2014, as further amended by the Second Amendment
to License Agreement effective as of March 17, 2015, as further amended by the Third Amendment to License Agreement effective as of September 8, 2016, as further amended by the Fourth Amendment to License Agreement effective as of
May 12, 2018, and as further amended by the Fifth Amendment to License Agreement effective as of March 1st 2021. 
 1.15.
“BCM Patents” means (a) the patents and patent applications set forth in Exhibit B and (b) any reissue, divisional, continuation, reexamination, renewal, extension or supplementary protection certificate for each of
the patents and patent applications set forth in Exhibit B either now pending or pending in the future, including all foreign and international counterparts and related patents and patent applications either now pending or pending in the
future. 
 1.16. “Business Day” means any day that is not a Saturday, a Sunday or another day on which banks are
required or authorized by Applicable Laws to be closed in New York, New York, U.S. 
 1.17. “CDMCs” means contract
development and manufacturing companies. 
 1.18. “Clinical Supply and Quality Agreement” has the meaning set forth
in Section 3.2(e). 
 1.19. “Commercial Supply and Quality Agreement” has the meaning set
forth in Section 4.2. 
 1.20. “Commercialize” or “Commercialization”
means any and all activities effective to market, promote, advertise, sell, offer for sale, have sold or otherwise dispose of, transport, distribute, import or export, as well as branding, preparation for the launch and medical education regarding,
Product, and interacting with Regulatory Authorities in connection with any of the foregoing after all Regulatory Approvals have been obtained in the applicable country. The term “Commercialized” has a correlative meaning. 

  
 3 

 1.21. “Commercially Reasonable Efforts” means, with respect to the
efforts to be expended by a Party pertaining to a particular objective, the efforts and resources commonly used by a similarly situated (with respect to size, stage of development and assets) biotechnology or pharmaceutical company for similarly
situated pharmaceutical products or product candidates, as applicable, to accomplish a similar objective under similar circumstances exercising reasonable business judgment, taking into account the following factors to the extent applicable:
(a) stage of development; (b) efficacy and safety issues; (c) characteristics of competitive products in or anticipated to be in the marketplace as well as the nature and extent of market exclusivity (including patent coverage and
regulatory exclusivity) and any Third Party intellectual property rights; (d) process development, scale-up or manufacturing; (e) cost and likelihood of obtaining regulatory approval; (f) actual
or anticipated regulatory authority approved labeling; and (g) projected or actual economic return. Commercially Reasonable Efforts will be determined on a
country-by-country and indication-by-indication basis for Product, and it is anticipated
that the level of effort may be different for different countries and indications, and may change over time, reflecting changes in the status of Product (including relative to this Agreement) and the country(ies) and indication(s) involved. 

1.22. “Confidential Information” means all information and Know-How and any
tangible embodiments thereof and other materials provided by or on behalf of the Disclosing Party to the Receiving Party either in connection with the discussions and negotiations pertaining to this Agreement or in the course of performing this
Agreement or that otherwise relates to Acer’s Technology, whether disclosed orally, visually, electronically, in writing or in other tangible or intangible form, and which may include data, knowledge, practices, processes, ideas, research
plans, antibodies, small molecules, compounds, targets, biological and chemical formulations, structures and designs, laboratory notebooks, proof of concept and pre-clinical studies, formulation or
manufacturing processes and techniques, scientific, manufacturing, marketing and business plans, and financial and personnel matters relating to the Disclosing Party or to its present or future products, sales, suppliers, customers, employees,
investors or business; provided, that information, materials or Know-How of a Party will not be deemed Confidential Information of such Party for purposes of this Agreement if such information,
materials or Know-How: (a) was already known to the Receiving Party, other than under an obligation of confidentiality or non-use, at the time of disclosure to such
Receiving Party, as can be shown by written records; (b) was generally available or known to parties reasonably skilled in the field to which such information or Know-How pertains, or was otherwise part
of the public domain, at the time of its disclosure to such Receiving Party; (c) became generally available or known to parties reasonably skilled in the field to which such information or Know-How
pertains, or otherwise became part of the public domain, after its disclosure to such Receiving Party through no fault of the Receiving Party; (d) was disclosed to such Receiving Party, other than under an obligation of confidentiality or non-use, by a third party who had no obligation to the Disclosing Party not to disclose such information or Know-How to others; or (e) was independently discovered or
developed by such Receiving Party, as can be shown by their written records, without the use of Confidential Information belonging to the Disclosing Party and prior to any subsequent disclosure by the Receiving Party; and provided, further, that
Confidential Information, to the extent relating to Acer’s Technology, will be deemed Confidential Information of Acer. 
 1.23.
“Control” means, with respect to any item of Know-How, Patent Rights or other intellectual property rights, the ability and authority of a Party or its Affiliates, whether arising by
ownership, possession, or pursuant to a license or sublicense (other than by operation of the license and other rights granted in this Agreement) or a right to acquire (by option or otherwise), to grant licenses, sublicenses or other rights to the
other Party under or to such item of Know-How, Patent Rights or other intellectual property rights as provided for in this Agreement, without breaching the terms of any agreement between such Party and any
Third Party. The term “Controlled” will be construed accordingly. 

  
 4 

 1.24. “Cost of Goods Sold” means, as to Product in the Acer
Territory, the fully burdened cost of such Product in final marketed form, which will (a) be determined in accordance with GAAP as applied by Acer (as the Party performing or contracting for each stage of the manufacturing process) and
(b) include direct labor, material, product testing costs and Allocable Overhead. 
 1.25. “Cost of Sales”
means, as to Product in the Acer Territory, Cost of Goods Sold, Third Party Royalties and outbound freight on sales if borne by the seller. 

1.26. “Cover” means, with respect to any Patent Right, that the use, manufacture, sale, offer for sale, research,
development, commercialization, importation or other commercial exploitation of the subject matter in question by an unlicensed entity would infringe an issued or pending claim of such Patent Right. 

1.27. “Development” (with a correlative meaning for “Develop,” “Developing” and
“Developed”) means all activities that relate to the development of Product or that are necessary or useful to obtain or maintain regulatory approval for Product, including all non-clinical studies
and clinical trials of Product, technology transfer, manufacture process development, manufacture and distribution of Product for use in clinical trials (including placebos and comparators), statistical analyses and the preparation and submission of
regulatory materials and other regulatory activities related to Product. 
 1.28. “Development Activities” means all
Development activities performed by or on behalf of either or both Parties pursuant to this Agreement. 
 1.29. “Development
Costs” mean, as to Product in the Acer Territory, costs, including Allocable Overhead, required to obtain the authorization or ability to manufacture, formulate, fill, ship or sell Product in commercial quantities. Development Costs will
include but are not limited to the following: (a) costs of studies on the toxicological, pharmacokinetic, metabolic or clinical aspects of Product (whether conducted internally or externally) for the purpose of obtaining or maintaining
regulatory approval of Product by a government organization in a country in the Acer Territory; (b) costs of preparing, submitting, reviewing or developing data or information for the purpose of a submission to a governmental authority to
obtain or maintain regulatory approval of Product in a country in the Acer Territory; (c) costs of process development scale-up and recovery (including plant costs); (d) costs of post-launch clinical
studies in support of Product in the Acer Territory; and, as applicable, (e) expenses for compensation, benefits and travel and other employee-related expenses, as well as data management, statistical designs and studies, document preparation
and other expenses associated with the clinical testing program. 
 1.30. “Development Data” means all data
generated by or on behalf of Relief or its Affiliates or Acer or its Affiliates in the course of, and as a result of, the performance of the Development Activities and directly relating to the Development of Product in a Territory (before or after
the Effective Date), including data related to all non-clinical studies and clinical trials of such Product, which for clarity may include data from clinical trials in the U.S. and the European Union,
technology transfer, manufacture process development, manufacture and distribution of such Product for use in clinical trials (including placebos and comparators), statistical analyses, and the preparation and submission of regulatory materials and
other regulatory activities related to such Product. 

  
 5 

 1.31. “Development Payments” has the meaning set forth in
Section 5.2(d). 
 1.32. “Development Plan” has the meaning set forth in
Section 2.2(b). 
 1.33. “Disclosing Party” has the meaning set forth in
Section 8.1. 
 1.34. “Distribution Costs” mean, as to Product in the Acer Territory, the
costs, including Allocable Overhead, specifically identifiable to the distribution of Product including the following: (a) costs of all aspects of order processing, invoicing, credit and collection; (b) costs of handling returns and
recalls; (c) costs of distribution, warehousing, inventory and receivables; (d) costs of collection of data of sales to hospitals and other end users; and (e) costs of all customer service related functions. 

1.35. “Effective Date” has the meaning set forth in the preamble. 

1.36. “European Union” means the economic, scientific and political organization of European Union member states as it
may be constituted from time to time, specifically including any territory that was a European Union member state as of the Effective Date, whether or not such territory is a participating member as of the applicable time. 

1.37. “Executive Officers” has the meaning set forth in Section 11.2. 

1.38. “Export Control Laws” means all applicable U.S. laws and regulations relating to (a) sanctions and
embargoes imposed by the Office of Foreign Assets Control of the U.S. Department of Treasury or (b) the export or re-export of commodities, technologies, or services, including the Export Administration
Act of 1979, 24 U.S.C. §§ 2401-2420, the International Emergency Economic Powers Act, 50 U.S.C. §§ 1701-1706, the Trading with the Enemy Act, 50 U.S.C. §§ 1 et. seq., the Arms Export Control Act, 22 U.S.C. §§
2778 and 2779, and the International Boycott Provisions of Section 999 of the U.S. Internal Revenue Code of 1986 (as amended). 

1.39. “FCPA” means the U.S. Foreign Corrupt Practices Act (15 U.S.C. Section 78dd-1, et. seq.), as amended. 
 1.40. “FDA” means the U.S. Food and Drug
Administration or any successor Regulatory Authority thereto in the U.S. having substantially the same function. 
 1.41.
“Field” means all indications or treatments of humans using Product. 
 1.42. “First Commercial
Sale” means, with respect to Product and a Party, on a country-by-country basis, the first sale by such Party or its Affiliates, or their respective licensees,
assignees or successors, for value for end use or consumption of Product in a country in the Acer Territory (where the Party is Acer) or in the Relief Territory (where the Party is Relief) after the governing Regulatory Authority of such country has
granted Regulatory Approval of such Product. For clarity, any sale of Product prior to receipt of Regulatory Approval, such as compassionate use, named patient use, clinical trial purposes or other similar uses, will not constitute a First
Commercial Sale. 

  
 6 

 1.43. “Fully Burdened Manufacturing Cost” means the cost per unit
for manufacture and supply plus all costs reasonably allocable per GAAP to the retention, establishment, qualification and maintenance of one or more CDMCs for manufacture and supply, including all costs incurred independent of the incremental cost
per unit for manufacture and supply, plus Acer’s FTE Costs for the foregoing (including Allocable Overhead). 
 1.44.
“FTE” means a total of 49 weeks or 1960 hours per year of work on Development or Commercialization of Product carried out by employees, consultants or representatives of a Party having the appropriate relevant expertise to conduct
such activities. 
 1.45. “FTE Costs” mean the number of relevant FTEs multiplied by the applicable FTE rate, with
FTE rates to be mutually agreed upon and set consistent with industry standards taking into account employee function, role and geographic location. 

1.46. “GAAP” means (a) generally accepted accounting principles in the U.S. or internationally, as appropriate,
consistently applied, or (b) the international financial reporting standards (“IFRS”) if a Party uses IFRS, consistently applied. 

1.47. “GCP” means the Good Clinical Practices officially published by the European Medicines Agency and any successor
agency, the FDA and the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) that may be in effect from time to time and are applicable to the Development of Product. 

1.48. “Generic Product” means a product (other than Product being Commercialized by a Party or its Affiliates, or
their respective licensees, assignees or successors) that (i) [***], and (ii) is bioequivalent, as determined by the relevant Regulatory Authority, to Product being Commercialized by a Party or its Affiliates, or their respective licensees,
assignees or successors. 
 1.49. “GMP” means those laws and regulations applicable in the U.S. and European Union,
relating to the manufacture of medicinal products for human use, including current good manufacturing practices as specified in the ICH guidelines, including ICH Q7A “ICH Good Manufacturing Practice Guide for Active Pharmaceutical
Ingredients,” US Federal Food Drug and Cosmetic Act at 21CFR (Chapters 210, 211, 600 and 610) and the Guide to Good Manufacturing Practices for Medicinal Products as promulgated under European Directive 91/356/EEC that may be in effect from
time to time and are applicable to the Development or manufacture of Product. 
 1.50. “Improvements” means any
invention, discovery, advancement, development, creation, and intellectual property (including patent, copyright, trade secret and application of patent) which: (a) is invented, developed, authored, created, or reduced to practice by or on
behalf of Relief or an Affiliate of Relief (or Relief’s or its Affiliate’s personnel or agents, including any employee, officer, advisor, or independent contractor employed or engaged by (or otherwise having an obligation to assign
inventions to) Relief or its Affiliates); and/or (b) is invented, developed, authored, created, or reduced to practice by or on behalf of Acer or an Affiliate of Acer (or Acer’s or its Affiliate’s personnel or agents, including any
employee, officer, advisor, or independent contractor employed or engaged by (or otherwise having an obligation to assign inventions to) Acer or its Affiliates) and (c) is not an Independent Invention; and (d) meets at least one of the
following criteria: (i) is an improvement or modification to the Acer Technology (including but not limited to improvements or modifications to Product or its formulation and use of Product alone or in combination with other drugs); (ii)
utilizes, incorporates, or reads upon any element of the Acer Technology; and (iii) is invented, developed, authored, created, or reduced to practice using the Acer Technology. 

  
 7 

 1.51. “IND” means an investigational new drug application, clinical
trial application, clinical trial exemption or similar application or submission filed with or submitted to a Regulatory Authority in a jurisdiction that is necessary to commence human clinical trials in such jurisdiction, including any such
application filed with the FDA pursuant to 21 C.F.R. Part 312. 
 1.52. “Independent Invention” means any invention,
discovery, advancement, development, creation, and intellectual property (including patent, copyright, trade secret and application of patent) which: (a) is invented, developed, authored, created, or reduced to practice by or on behalf of
Relief or an Affiliate of Relief (or the personnel or agents of Relief or an Affiliate of Relief, including any employee, officer, advisor, or independent contractor employed or engaged by (or otherwise under an obligation to assign inventions to)
Relief or an Affiliate of Relief); (b) does not utilize, incorporate, or read upon any element of the Acer Technology and is not invented, developed, authored, created, or reduced to practice using the Acer Technology; (c) is not to any extent
invented, developed, authored, created, or reduced to practice by Acer (or Acer’s personnel or agents, including any employee, officer, advisor, or independent contractor employed or engaged by (or otherwise under an obligation to assign
inventions to) Acer); and (d) is not related to, and does not arise from the performance of, any of the performance, transactions or arrangements contemplated by this Agreement, including Development or Commercialization. 

1.53. “JSC” has the meaning set forth in Section 2.1. 

1.54. “Know-How” means tangible and intangible information, techniques,
technology, practices, trade secrets, inventions (whether patentable or not), processes, formulations, compounds, products, biological materials, cell lines (it being understood that any rights to use
“Know-How” include the rights to use such cell lines), samples of assay components, media, designs, formulas, ideas, programs, software models, algorithms, developments, experimental works,
protocols, methods, knowledge, know-how, skill, experience, test data and results (including pharmacological, toxicological and non-clinical and clinical data and
results), compilations of data, other works of analytical and quality control data, results, descriptions, compositions of matter, regulatory submissions, minutes, correspondence and strategy. 

1.55. “Launch Costs” has the meaning set forth in Section 5.2(d). 

1.56. “Losses” has the meaning set forth in Section 7.1. 

1.57. “Loss of Market Exclusivity” means, on a
country-by-country and indication-by-indication basis, one or more products are marketed
in the country at issue for the indication at issue (a) each of which is a Generic Product, (b) each of which is approved in reliance on, and by reference to, the Regulatory Approval of Product being Commercialized by a Party or its
Affiliates, or their respective licensees, assignees or successors, and (c) collectively capture at least 50% (by value) of all products that are bioequivalent to Product being Commercialized by a Party or its Affiliates, or their respective
licensees, assignees or successors, in such country for such indication for the prior 12-month period. 

  
 8 

 1.58. “Marketing Costs” mean, as to Product in the Acer Territory,
the costs, including Allocable Overhead, of marketing, promotion, advertising, professional education, Product-related public relations, relationships with opinion leaders and professional societies, market research, healthcare economics studies and
other similar activities directly related to Product. Such costs will include both Acer internal costs (e.g., salaries, benefits, supplies and materials, etc.) as well as outside services and expenses (e.g., consultants, agency fees, meeting costs,
etc.). Marketing Costs will also include activities related to obtaining reimbursement from payers and costs of sales and marketing data. Marketing Costs will specifically exclude the costs of activities which promote (a) Acer’s business
as a whole without being specific to Product (such as corporate image advertising) or (b) products other than Product. 
 1.59.
“Milestone Payments” mean, collectively, the MSUD Milestone Payment and UCD Milestone Payment. 
 1.60.
“MSUD” means maple syrup urine disease. 
 1.61. “Net Profits in the Acer Territory” mean, as to
Product for a given period, the sum of the following for such period: (a) Net Sales in the Acer Territory; less (b) each of the following items: (i) Cost of Sales; (ii) Development Costs;
(iii) Distribution Costs; (iv) Marketing Costs; (v) Other Operating Expense; (vi) Sales Costs; and (vii) any other FTE Costs of Acer associated with but not otherwise covered by any of the foregoing (“Other
Costs”); provided, however, that for the avoidance of doubt, any Launch Costs which are covered by the Development Payments will not be deducted from Net Sales in the Acer Territory for purposes of calculating Net Profits in
the Acer Territory. 
 1.62. “Net Profit Term” means, on a country-by-country and indication-by-indication basis (but solely as to countries within the Acer Territory), the period from
the Effective Date until the date when the later of the following three events to occur: (a) the last Acer Patent expires that Covered the manufacture, use, sale, offer for sale or import of Product in that country for such indication;
(b) twelve (12) years from the First Commercial Sale of Product in that country for such indication; or (c) Loss of Market Exclusivity. 

1.63. “Net Sales” mean the gross amount of monies or cash equivalent or other consideration which is received for
sales, leases or other modes of transfer of Product by a Party or its Affiliates, or their respective licensees, assignees or successors, to a non-affiliated third party end user customer (subject to the Third
Party List Price) less: (a) customary trade, quantity or cash discounts and rebates to the extent actually allowed and taken; (b) amounts repaid or credited to customers by reason of rejections or returns made of previously sold Product
based on product defect; (c) to the extent separately stated on purchase orders, invoices or other documents of sale, taxes or other governmental charges (except filing fees) which are actually paid by or on behalf of a Party or its Affiliates,
or their respective licensees, assignees or successors, for the production, sale, transportation, delivery or use of Product; and (d) reasonable charges for delivery or transportation of Product to customers through the use of third party
delivery or transportation services, if separately stated and not charged to or reimbursed by the customer (provided, that in the calculation of Net Profits in the Acer Territory, any charges in this clause (d) shall not be deducted more than
once – such as, for example, a potential second deduction as a portion of Distribution Costs). The term “Net Sales” in the case of non-cash sales means the fair market value of all equivalent or
other consideration received by a Party or its Affiliates, or their respective licensees, assignees or successors, for the sale, lease or transfer of Product to third party end user customers (subject to the Third-Party List Price). For clarity:
(i) if a Party or its Affiliate sells or transfers Product to a licensee, Net Sales are to be calculated on such licensee’s sale to a third party and not on the sale or transfer price to such Party or its Affiliate; and (ii) if a
Party or its Affiliate, or any licensee thereof, sells or transfers Product to a third party such as a wholesaler, specialty pharmacy, distributor or reseller that will conduct a further sale or transfer to a third party end user customer or other
third party reseller, then Net Sales are to be calculated on the list price of such Party or its Affiliate, or any licensee thereof, as applicable (the “Third-Party List Price”). If no Third-Party List Price is determined, then the
Parties will agree in writing to an appropriate list price. 

  
 9 

 1.64. “NDA” means a new drug application required for Regulatory
Approval as a pharmaceutical product by the FDA or an equivalent application to the equivalent agency in any other country or group of countries (e.g., the marketing authorization application in the EU (“MAA”)). 

1.65. “Other Operating Expense” means, as to Product in the Acer Territory, other operating expense which is not
otherwise covered, including the following: (a) expenses of inventory write-offs; (b) the costs and expenses of prosecuting and maintaining patents and patent applications; (c) the costs and expenses of enforcing intellectual property
rights or defending against the assertion of intellectual property rights; and (d) product liability insurance. 
 1.66.
“Party” or “Parties” has the meaning set forth in the preamble. 
 1.67. “Patent Rights”
means (a) the Acer Patents and (b) the BCM Patents. 
 1.68. “Product” means a pharmaceutical composition
or preparation which consists of or includes a taste-masked, immediate release formulation of sodium phenylbutyrate (“NaPB”), including for the potential treatment of various inborn errors of metabolism such as UCDs and MSUD. 

1.69. “Receiving Party” has the meaning set forth in Section 8.1. 

1.70. “Regulatory Approval” means all approvals, including pricing approvals, that are necessary for the commercial
sale of Product in a given country. 
 1.71. “Regulatory Authority” means any country, federal, supranational, state
or local regulatory agency, department, bureau or other governmental or regulatory authority having the administrative authority to regulate the development or marketing of pharmaceutical products in any country, including the FDA and the European
Medicines Agency. 
 1.72. “Reimbursement Payment” has the meaning set forth in
Section 5.2(a). 

  
 10 

 1.73. “Relief” has the meaning set forth in the preamble. 

1.74. “Relief Indemnitees” has the meaning set forth in Section 7.2. 

1.75. “Relief Termination” has the meaning set forth in Section 3.3(a). 

1.76. “Relief Territory” means the world except for the Acer Territory. 

1.77. “Royalty Term” means, on a
country-by-country and indication-by-indication basis (but solely as to countries within
the Relief Territory), the period from the Effective Date until the date when the later of the following three events occurs: (a) the last Acer Patent expires that Covered the manufacture, use, sale, offer for sale or import of Product in that
country for such indication; (b) twelve (12) years from the First Commercial Sale of Product in that country for such indication; or (c) Loss of Market Exclusivity. 

1.78. “Sales Costs” mean, as to Product in the Acer Territory, costs, including Allocable Overhead, identifiable to
the sales of Product to all markets (including the managed care market), including the following: (a) costs associated with sales representatives, including compensation, benefits and travel; (b) the
start-up and ongoing ramping costs associated with a sales force, including recruiting, relocation and other similar costs; (c) costs associated with supervision and training of sales representatives;
(d) costs associated with sales meetings; and (e) other sales expenses. 
 1.79. “Significant European
Market” means Germany, Spain, United Kingdom, France or Italy. 
 1.80. “Subject Technology” has the
meaning prescribed to it under the BCM License. 
 1.81. “Term” has the meaning set forth in
Section 10.1. 
 1.82. “Territories” means, collectively, the Acer Territory and the
Relief Territory. 
 1.83. “Third Party” means any person or entity other than Relief or Acer or an Affiliate of
either Party. 
 1.84. “Third Party Claim” has the meaning set forth in Section 7.1. 

1.85. “Third Party Royalties” mean royalties and other payments (including any upfront fees and milestone payments)
payable to a Third Party in connection with the manufacture, use, offer for sale, sale or import of Product in the Acer Territory. 

1.86. “UCD(s)” means urea cycle disorder(s). 

1.87. “U.S.” means the United States of America and its territories and possessions. 

1.88. “U.S. Launch Plan” means the initial plan and budget for Development and Commercialization activities leading up
to commercial launch of Acer Product in the U.S. for UCD and MSUD, which have been exchanged between and agreed to by the Parties prior to the Effective Date. 

  
 11 

 ARTICLE 2 

GOVERNANCE 
 2.1.
Joint Steering Committee. The Parties hereby establish a joint steering committee (the “JSC”) to oversee and coordinate Development and Commercialization in the Acer Territory and the Relief Territory, and to encourage and
facilitate the ongoing cooperation and communication between the Parties regarding matters related to such activities. 
 2.2. The JSC
will in particular: 
 (a) Review and approve any material changes to the U.S. Launch Plan; 

(b) Other than the U.S. Launch Plan, review and approve the plans for Development of Product (each, including as amended, a
“Development Plan”) in any jurisdiction, whether leading up to Regulatory Approval or following Regulatory Approval, and any material modifications to any such Development Plan; 

(c) Monitor progress of each Development Plan, review relevant Development Data and timely share information on progress of
Development; 
 (d) Review Acer’s contractual establishment, qualification and maintenance of the manufacturing facilities and
processes for purposes of manufacture and supply of Product for Development and Commercialization; 
 (e) Decide to advance, suspend
or terminate Development of Product (on a country-by-country and indication-by-indication
basis) at key decision points, including, but not limited to, the initiation or continuation of clinical trials and filing of applications for Regulatory Approval; 

(f) Other than the U.S. Launch Plan, review and approve plans for Commercialization of Product in any jurisdiction, including with
respect to identifying jurisdictions to pursue and access to those markets, activities leading up to launch in such jurisdiction of Product, reimbursement status of Product in a jurisdiction, and other relevant considerations for Commercialization
in a particular jurisdiction; 
 (g) Serve as a forum for the discussion of any safety, scientific or technical concerns regarding
Development, Commercialization or the manufacture and supply of Product; 
 (h) Serve as a forum for the discussion of intellectual
property strategy with respect to Product, including reviewing and updating such strategy; and 
 (i) Perform such other appropriate
activities and functions and make such other appropriate decisions as agreed by the Parties in writing. 

  
 12 

 2.3. Limitations of JSC Authority. The JSC will only have the powers expressly
assigned to it in this Article 2 and elsewhere in this Agreement and will not have the authority to: (a) modify or amend the terms and conditions of this Agreement; or (b) decide any issue in a manner that would conflict with the
express terms and conditions of this Agreement. 
 2.4. JSC Membership and Meetings. 

(a) JSC Members. The JSC will consist of six (6) members, with three (3) appointed by Acer and three
(3) appointed by Relief, each of whom will have appropriate technical credentials, experience, knowledge and authority within such Party’s organization and one (1) of such appointed members of the JSC by each Party will be a key
person (each, a “Key Person”) to oversee such Party’s efforts with respect to Development and Commercialization in its Territory. Initial members for the JSC will constitute: Relief nominees, Raghuram (Ram) Selvaraju, Paul
Waymack, and a third person to be identified by Relief to Acer in writing prior to the first meeting of the JSC; and Acer nominees, Chris Schelling, John Klopp and Matt Seibt. Within thirty (30) days following the Effective Date, each Party
will designate its initial Key Person. Each Party may replace its representatives on the JSC by written notice to the other Party. The Parties will alternate, on a
meeting-by-meeting basis, in appointing one (1) of their representatives on the JSC to act as the chairperson of the JSC for the meeting. The chairperson will
prepare and circulate agendas prior to each JSC meeting and subsequently promptly provide to the Parties reasonably detailed drafts of the minutes of each such meeting. The Parties will promptly discuss any comments on such minutes and finalize the
minutes no later than seven (7) days prior to the date of the next JSC meeting. 
 (b) Meetings. The JSC will hold
meetings at such times as it elects to do so, but such meetings will be held at least once every calendar month unless the JSC decides on a different frequency. Meetings of the JSC may be held in person, or by audio or video teleconference, at the
JSC’s discretion, with in-person JSC meetings being held at locations selected on an alternating basis by the Parties. Each Party will be responsible for all of its own expenses in connection with
participating in the JSC meetings. 
 (c) Non-Member Attendance. Each Party may from
time to time invite a reasonable number of its representatives, who are not members of the JSC, to attend the JSC meetings in a non-voting capacity; provided, that such participants are bound by
confidentiality and non-use obligations consistent with the terms of this Agreement; and provided, further, that each Party will provide reasonable prior written notice to the other Party if it has invited any
Third Party (including any consultant) to attend such a meeting and the attendance of such Third Party will be subject to the consent of the other Party. 

2.5. Decision-Making. 

(a) All decisions of the JSC will be made by unanimous vote, with each Party’s representatives collectively having one
(1) vote. No vote of the JSC may be taken unless at least one of each Party’s representatives is present for the vote. Each Party will be responsible for ensuring that, at all times, its representatives on the JSC act reasonably and in
good faith in carrying out their respective responsibilities hereunder. 

  
 13 

 (b) If the JSC cannot reach consensus with regard to any matter within its authority
within fifteen (15) Business Days after such matter has been presented for the JSC’s attention, then split decisions will be decided by the Relief representatives to the extent primarily related to Development or Commercialization in the
Relief Territory and by the Acer representatives to the extent primarily related to Development and Commercialization in the Acer Territory. Notwithstanding the foregoing, any split decision regarding any other matter or any split decision by the
JSC that relates to safety or chemistry, manufacturing and controls (CMC) will be resolved only following good faith discussions between the Executive Officers (as defined below) to resolve such issue within fifteen (15) Business Days from the
date upon which such matter is referred to them. In the event that such Executive Officers are unable to resolve such issue within fifteen (15) Business Days of the issue being referred to them, then Acer’s Executive Officer will have the tie-breaking vote; provided, however, that, in each case, Acer’s Executive Officer will give good faith consideration to Relief’s position and make reasonable efforts to take Relief’s position
into account in making such decision. 
 ARTICLE 3 

DEVELOPMENT 
 3.1.
Technology Transfer for Developing Product. At Relief’s expense (including Acer’s FTE Costs and out-of-pocket expenses in connection therewith), Acer
will transfer Acer Know-How to Relief starting within fifteen (15) Business Days after the Effective Date for Development in the Relief Territory, including all information to the extent in its possession
concerning Acer Product necessary for the Development and Commercialization thereof, including information regarding its characterization, summaries of the status of its Development, all INDs filed anywhere in the world with respect to Acer Product,
all human clinical trial data and results related to Acer Product and all existing IND-enabling data. For avoidance of doubt, Acer’s obligation to support and provide Relief with Acer Know-How shall be ongoing throughout the Term of this Agreement. 
 (a) Upon Relief’s request,
Acer shall provide Relief with all then currently available Development Data and other information that is necessary or reasonably useful for Relief to Develop and Commercialize the Acer Product in the Relief Territory. Any unreasonable delay by
Acer in providing information that is necessary or useful in the Development or Commercialization of the Acer Product in the Relief Territory shall toll the time for Relief to meet the timing requirements set forth in
Section 3.2 and will be extended by the amount of time of Acer’s unreasonable delay. 
 (b) The
Parties shall each prepare quarterly written updates on Improvements and the Acer Technology, which shall include at least a description of (i) newly developed Improvements and Acer Know-How,
(ii) strategy and activities for further Improvements and Acer Know-How, and (iii) current status, strategy, and activities for Acer Patents, BCM Patents and patenting of any Improvements, which
updates shall be provided to the JSC in advance of the next scheduled JSC meeting as set forth in Section 2, and each Party shall have the right to reasonably request additional information from the other Party regarding
the status and progress in this regard. Such updates will include activities undertaken by or on behalf of each Party since the last update was delivered, and the activities undertaken by or on behalf of each Party during the next twelve (12)-month
period and the expected timing of such activities (including the estimated dates of initiation and completion of such activities). 

  
 14 

 3.2. Development. Each Party will be responsible, at its own expense, for
conducting Development in its Territory and as set forth in this Section 3.2. 
 (a) Each Party will
exercise Commercially Reasonable Efforts for Development in its Territory. Acer will be deemed to have exercised Commercially Reasonable Efforts for Development in the Acer Territory if an NDA is submitted to the FDA for use of Acer Product in a UCD
within five (5) months of a successful pre-NDA meeting with the FDA. Relief will be deemed to have exercised Commercially Reasonable Efforts for Development in the Relief Territory if: (i) the First
Commercial Sale of Product in a UCD by Relief occurs in at least one Significant European Market prior to the later of (A) December 31, 2023 or (B) twelve (12) months following Regulatory Approval by the FDA for use of Acer Product in
a UCD; or (ii) Relief submits an MAA for use of Acer Product in MSUD in at least one Significant European Market no later than twelve (12) months following Regulatory Approval by the FDA for use of Acer Product in MSUD. 

(b) Acer will provide Relief with reasonable assistance for Regulatory Approvals in the Relief Territory at Relief’s expense,
including Acer’s FTE Costs and out-of-pocket expenses in connection therewith. 

(c) Neither Party will take action in respect of Development in its Territory that would reasonably be expected to materially adversely
impact the ability of the other Party to obtain Regulatory Approval or to Commercialize in the other Party’s Territory. 
 (d)
At Relief’s expense, Acer will supply Acer Product to Relief for Development in the Relief Territory at Acer’s Fully Burdened Manufacturing Cost. Such supply will be subject to a separate Clinical Supply and Quality Agreement (the
“Clinical Supply and Quality Agreement”) to be negotiated in good faith (based on Acer’s agreements with Third Party CDMCs for the manufacture and supply of Acer Product) promptly following the Effective Date. 

(e) All Development of Product in the Relief Territory will be set forth in a series of Development Plans approved by the JSC. 

3.3. Relief Termination. 

(a) Notwithstanding any other provision of this Agreement to the contrary, Relief may for any reason in its sole discretion decide on
three (3) months’ written notice (or any shorter period to which Acer agrees in its sole discretion) to not proceed with Development and Commercialization in all countries within the Relief Territory or Relief may decide on thirty
(30) days written notice (or any shorter period to which Acer agrees in its sole discretion) delivered not before January 3, 2022 to not proceed with Development and Commercialization in all countries within the Relief Territory if an NDA
for the Acer Product for a UCD has not been accepted for review by the FDA (a “Relief Termination”), in which case (A) Relief will not be responsible for any further monetary or other obligations to Acer that accrue following a
Relief Termination, but without limiting its obligations for activities and obligations prior to such cessation, (B) all payments made by Relief as of the Relief Termination (i.e., Milestone Payments, the Reimbursement Payment, the Development
Payments (notwithstanding the provisions of Section 5.2(d) for this purpose) and any other payments and reimbursements) are non-refundable and (C) all rights and data with
respect to Product will thereupon revert or transfer to Acer; provided, however, that after commercial launch of Product occurs in at least one Significant European Market, Relief may decide to not proceed with Development and
Commercialization in one or more countries within the Relief Territory which are identified to Acer in writing (the “Excluded Countries”) without triggering a Relief Termination so long as Relief continues to exercise Commercially
Reasonable Efforts for Development and Commercialization for the remaining countries within the Relief Territory and otherwise performs this Agreement in accordance with its terms, with Relief agreeing that any Excluded Countries shall, following
such identification by Relief to Acer in writing, be excluded from the Relief Territory for purposes of this Agreement. 

  
 15 

 (b) In the event of a Relief Termination, (i) the Acer Territory will be the
entire world for purposes of Product, (ii) all rights and responsibilities of Relief with respect to Development will revert to Acer, (iii) Relief will transfer sponsorship of the management of any Development in the Relief Territory to
Acer to the extent requested by Acer and (iv) Acer will thereafter be free to Develop and Commercialize anywhere in the world in its sole discretion and at its sole expense, provided that Relief will be responsible for the monetary
obligations under Article 5 accrued as of the Relief Termination. 
 (c) If a clinical trial for Product is terminated or any
Development is ended while a clinical trial is ongoing (the “Terminated Trial”), then the Party responsible for the Territory in which the Terminated Trial occurred will be responsible for the orderly wrapping up of such trial
consistent with good clinical practices and the costs of such activities. 
 3.4. Performance by the Parties. Each Party will
perform Development Activities in in accordance with the terms and conditions of this Agreement and Applicable Laws, including GCP and GMP to the extent applicable. If there is any conflict between performance in accordance with Applicable Laws and
this Agreement, performance in accordance with Applicable Laws will prevail. 
 3.5. Safety Data Exchange. The Parties will
negotiate in good faith promptly following the Effective Date a safety data exchange agreement regarding Product, which will set forth standard operating procedures governing the collection, investigation, reporting and exchange of information
concerning adverse drug reactions/experiences sufficient to permit each Party to comply with its regulatory and other legal obligations within the applicable timeframes (the “Pharmacovigilance Agreement”). The Pharmacovigilance
Agreement will (a) identify which Party will be responsible for the timely reporting of all relevant adverse drug reactions/experiences, Product complaints and safety data relating to Product to the appropriate Regulatory Authorities in both
the Relief Territory and the Acer Territory in accordance with all Applicable Laws and (b) allow each Party to comply with all regulatory and legal requirements regarding the management of safety data by providing for the exchange of relevant
information in the appropriate format within applicable timeframes. 

  
 16 

 ARTICLE 4 

COMMERCIALIZATION 

4.1. Commercialization of Product in the Territories. Relief will be responsible for and will use Commercially Reasonable
Efforts to Commercialize in the Relief Territory following Regulatory Approval. Acer will be responsible for and will use Commercially Reasonable Efforts to Commercialize in the Acer Territory following Regulatory Approval. Relief will have
exclusive rights to the respective Regulatory Approvals in the Relief Territory during the Term and Acer will own all Regulatory Approvals in the Territories. Neither Party will take action in respect of Commercialization in its Territory that would
reasonably be expected to materially adversely impact the ability of the other Party to obtain Regulatory Approval or to Commercialize in the other Party’s Territory. 

4.2. Commercial Supply. Acer will supply in bulk form Acer Product to Relief for Commercialization in the Relief Territory at
Acer’s Fully Burdened Manufacturing Cost. Such supply will be subject to a separate Commercial Supply and Quality Agreement (the “Commercial Supply and Quality Agreement”) to be negotiated in good faith (based on Acer’s
agreements with Third Party CDMCs for the manufacture and supply of Acer Product) following the Effective Date. Relief will be responsible for packaging, labelling, serialization and distribution of Product; provided, however, that, as will
be set forth in the Commercial Supply and Quality Agreement, Acer can either support content uniformity testing after packaging in pouches (all other release testing will be done on bulk drug product) or transfer the method to Relief. 

4.3. Product Recalls. In the event that any Regulatory Authority issues or requests a recall or takes similar action in
connection with Product, or in the event a Party reasonably believes that an event, incident or circumstance has occurred that may result in the need for a voluntary or mandatory recall, market withdrawal or other corrective action regarding
Product, such Party will promptly advise the other Party (in the case of Relief, the Chief Executive Officer or another senior executive designated in advance by the Chief Executive Officer; and in the case of Acer, the Chief Executive Officer or
another senior executive designated in advance by the Chief Executive Officer) thereof by telephone or email. Relief will decide and have control of whether to conduct a recall or market withdrawal (except in the event of a recall or market
withdrawal mandated by a Regulatory Authority, in which case it will be required) or to take other corrective action in any country in Relief Territory and the manner in which any such recall, market withdrawal or corrective action will be
conducted; provided, that Acer will have the right to participate in any meetings and to review and comment in advance on any communications with a Regulatory Authority in connection with a recall or pharmacovigilance matter in the Relief
Territory and Relief will notify Acer prior to making any public disclosure of the recall, market withdrawal or corrective action and will keep Acer regularly informed regarding any such recall, market withdrawal or corrective action. Recall costs
in the Relief Territory will be borne solely by Relief. Acer will decide and have control of whether to conduct a recall or market withdrawal (except in the event of a recall or market withdrawal mandated by a Regulatory Authority, in which case it
will be required) or to take other corrective action in any country in the Acer Territory and the manner in which any such recall, market withdrawal or corrective action will be conducted; provided, that Acer will notify Relief prior to
making any public disclosure of the recall, market withdrawal or corrective action and will keep Relief regularly informed regarding any such recall, market withdrawal or corrective action. Recall costs in the Acer Territory will be borne by the
Parties as they will be included in Distribution Costs. The Parties will exercise reasonable cooperation between them, as appropriate, to resolve Product complaints and share related data. 

  
 17 

 4.4. Pharmacovigilance. Unless otherwise set forth in the Pharmacovigilance
Agreement, the Parties will jointly maintain a global database with Relief responsible for all activities in the Relief Territory and Acer responsible for all activities in the Acer Territory. 

ARTICLE 5 
 FINANCIAL
PROVISIONS 
 5.1. Cost for Developing and Commercializing Product. Other than the payments to be made by Relief to Acer
pursuant to this Agreement and the costs that will be incorporated into the calculation of Net Profits in the Acer Territory, each Party will be responsible for the costs and expenses for Development (including Regulatory Approval) and
Commercialization in its respective Territory. 
 5.2. Reimbursement, Milestone and Development Payments. 

(a) Within fifteen (15) Business Days following the Effective Date, Relief will pay Acer Fourteen Million Dollars ($14,000,000),
which is a reimbursement to Acer for expenses related to Development prior to the Effective Date (the “Reimbursement Payment”); provided, however, that any portion of the Reimbursement Payment (up to the maximum amount owed)
may be offset, at the election of Relief, against the outstanding liability of Acer under that certain Promissory Note payable by Acer to Relief dated January 25, 2021 in the original principal amount Four Million Dollars ($4,000,000). For the
avoidance of doubt, the Reimbursement Payment will be fully earned and not contingent upon any future performance or occurrence. 

(b) Within fifteen (15) Business Days following Regulatory Approval in any country in the European Union of Acer Product for a
UCD, Relief will pay Acer Four Million Dollars ($4,000,000) (the “UCD Milestone Payment”). 
 (c) Within fifteen
(15) Business Days following the Regulatory Approval in any country in the European Union of Acer Product for MSUD, Relief will pay Acer Two Million Dollars ($2,000,000) (the “MSUD Milestone Payment”). 

(d) Relief will pay Acer Ten Million Dollars ($10,000,000) (the “First Development Payment”), of which $5,000,000 is
payable by April 30, 2021 and $5,000,000 is payable by June 30, 2021. Within fifteen (15) Business Days after the NDA for the Acer Product for a UCD has been accepted for review by the FDA, Relief will pay Acer another Ten Million
Dollars ($10,000,000) (the “Second Development Payment” and, with the First Development Payment, the “Development Payments”). The Development Payments will be used to pay for the costs and expenses of Development
following the Effective Date as well as Commercialization activities leading up to (and for) the commercial launch in the U.S. of Acer Product for UCD and MSUD pursuant to the U.S. Launch Plan, including Acer’s FTE Costs and out-of-pocket expenses in connection therewith (collectively, the “Launch Costs”). Acer shall provide Relief with invoices of such Development and Launch
Costs for reconciliation on a quarterly basis, within sixty (60) days from the end of each calendar quarter. If the First Commercial Sale of Acer Product by or on behalf of Acer in the U.S. for UCD or MSUD occurs prior to such Development and
Launch Costs aggregating Twenty Million Dollars ($20,000,000), then Acer shall promptly return to Relief, but not later than sixty (60) days following such First Commercial Sale, the difference between the amount of the Development Payments
received and the total of such Development and Launch Costs. For the avoidance of doubt, after the First Commercial Sale of Acer Product in the U.S. for UCD or MSUD, any Development Costs shall be part of the calculation of Net Profits in the Acer
Territory. 

  
 18 

 5.3. Commercialization of Product in the Relief Territory. From the Effective
Date through the end of the earlier of the Royalty Term or the termination of this Agreement, Relief shall pay to Acer fifteen percent (15%) of all Net Sales for each calendar quarter for Commercialization on a country-by-country and indication-by-indication basis in the Relief Territory (each, a “Royalty Payment”). 

5.4. Commercialization of Product in the Acer Territory. From the Effective Date through the end of the earlier of the Net
Profit Term or the termination of this Agreement, Acer shall pay to Relief sixty percent (60%) of all Net Profits in the Acer Territory for each calendar quarter for Commercialization on a country-by-country and indication-by-indication basis in the Acer Territory (each, a “Net Profit Payment”).

 5.5. Payments; Reports. All payments due from a Party under Sections 5.3 and 5.4 will be calculated and
reported to the other Party for each calendar quarter within thirty (30) days following the end of the applicable calendar quarter. Each Royalty Payment will include a report by Relief detailing the Net Sales in the Relief Territory for the
applicable calendar quarter with reasonable detail regarding the basis of the payment made, including, on a country-by-country basis, the volume of Product sold, the
gross sales and Net Sales of Product, the amount payable, the method used to calculate such amount and the exchange rates used. Each Net Profit Payment will include a report by Acer detailing the Net Profits in the Acer Territory for the applicable
calendar quarter with reasonable detail regarding the basis of the payment made, including, on a country-by-country basis, the volume of Product sold, applicable Net
Sales, Cost of Sales, Development Costs, Distribution Costs, Marketing Costs, Other Operating Expense, Other Costs and Sales Costs, the amount payable, the method used to calculate the such amounts and the exchange rates used. 

5.6. Currency; Exchange Rate. All payments to be made under this Agreement will be made in US Dollars by bank wire transfer in
immediately available funds to a bank account designated by written notice from the receiving Party. When conversion of payments from any foreign currency is required, such conversion will be at an exchange rate equal to the average of the daily
rates of exchange for the currency of the country from which such payments are payable as published by The Wall Street Journal, Western U.S. Edition during the quarter for which a payment is due. 

5.7. Late Payments. If a Party does not receive payment of any sum due to it on or before the due date therefor, simple interest
will thereafter accrue on the sum due to such Party from the due date until the date of payment at a per-annum rate of three percent (3%). The payment of such interest will not limit the Party entitled to
payment from exercising any other rights it may have as a consequence of the lateness of any payment. 

  
 19 

 5.8. Financial Records; Audit. 

(a) Each Party will keep, and require its Affiliates to keep, reasonably detailed, fair and true books of accounts and records for the
purpose of determining the amounts payable to the other Party pursuant to this Agreement. Such books and records will be kept for at least three (3) full years following the end of the year to which they pertain. 

(b) Each Party will allow an independent certified public accountant selected by the auditing Party and reasonably acceptable to the
audited Party to audit its records for such year to verify the accuracy of any financial report furnished by such Party and any amounts to be shared or paid under this Agreement for the preceding three (3) full years. Such audits may be
exercised during normal business hours upon reasonable prior written notice by a Party to the other Party. The cost of such any audit will be borne by the Party requesting such audit, unless the audit discloses an underpayment or an overpayment by
the audited Party of more than ten percent (10%) of the amount of payments due under this Agreement for any applicable quarter, in which case the audited Party will bear the cost of such audit. 

(c) Any amounts shown to be owed but unpaid, or overpaid and in need of refund, will be paid or refunded (as the case may be) within
twenty-five (25) days after the accountant’s report, plus interest (as set forth in Section 5.7) from the original due date. 

5.9. Tax. 

(a) Taxes on Income. Each Party will be solely responsible for the payment of all taxes imposed on its share of income, including any
payments received, as contemplated in this Agreement. 
 (b) Tax Cooperation. The Parties agree to cooperate with one another and use
reasonable efforts to avoid or reduce tax withholding or similar obligations in respect of any payments made by a Party to the other Party under this Agreement. 

(c) Payment of Tax. To the extent a Party is required by Applicable Laws to deduct and withhold taxes on any payment to the other
Party, the paying Party will pay the amounts of such taxes to the proper tax authority in a timely manner and promptly transmit to the other Party an official tax certificate or other evidence of such withholding sufficient to enable such other
Party to claim such payment of taxes. 
 ARTICLE 6 

REPRESENTATIONS, WARRANTIES AND COVENANTS 

6.1. Mutual Representations and Warranties. Each Party hereby represents, warrants and covenants (as applicable) to the other
Party as follows: 
 (a) Corporate Existence and Power. It is a company or corporation duly organized, validly existing and in good
standing under the laws of the jurisdiction in which it is incorporated, and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as
contemplated in this Agreement, including the right to grant the licenses granted by it hereunder. 

  
 20 

 (b) Authority and Binding Agreement. As of the Effective Date, (i) it has the
corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; (ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this
Agreement and the performance of its obligations hereunder; and (iii) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid and binding obligation of such Party that is enforceable against
it in accordance with its terms. 
 (c) No Conflict; Covenant. It is not a party to any agreement that would materially prevent it
from granting the rights granted to the other Party under this Agreement or performing its obligations under this Agreement. 
 (d)
Compliance with Law. It will comply in all material aspects with all Applicable Laws in the course of performing its obligations and exercising its rights under this Agreement. 

6.2. Additional Representations and Warranties of Acer. Acer represents, warrants and covenants (as applicable) to Relief that:

 (a) Acer (i) has the right to grant the Acer Technology License and the Acer Sublicense; and (ii) has not granted and
will not grant any right to any Third Party that would conflict with or adversely affect the Acer Technology License or the Acer Sublicense; 

(b) As of the Effective Date, there are no actual, pending or, to Acer’s knowledge, alleged or threatened adverse actions, suits,
proceedings or claims against Acer involving Product or Acer Technology, including but not limited to Acer’s ability to develop, make, have made, use, sell, have sold, offer to sell, Commercialize or import Product or Acer Technology, the
validity of the Acer Technology, or ownership of Product or Acer Technology, nor has Acer received any written communication from any Third Party, including any Regulatory Authority or other government agency, threatening such action, suit,
proceeding or claim; 
 (c) As of the Effective Date, neither Acer nor any of its Affiliates has filed any regulatory filing for
marketing approval of Product in the Relief Territory; 
 (d) Acer is not debarred or disqualified under the United States Federal
Food, Drug and Cosmetic Act or comparable Applicable Laws in the Territory and it has not employed or used the services of any person who is debarred or disqualified in connection with activities relating to any pharmaceutical products; and 

(e) As of the Effective Date and other than with respect to the matters described in Acer’s public filings, there are no legal
claims, judgments or settlements against or owed by Acer or any of its Affiliates or pending or, to Acer’s knowledge, threatened, in each case, relating to antitrust, anti-competition, anti-bribery, corruption violations, or other violations of
the securities laws of the United States. 

  
 21 

 6.3. Additional Representations and Warranties of Relief. Relief represents,
warrants and covenants (as applicable) to Acer that: 
 (a) Relief is not debarred or disqualified under the United States Federal
Food, Drug and Cosmetic Act or comparable Applicable Laws in the Territory and it has not employed or used the services of any person who is debarred or disqualified in connection with activities relating to any pharmaceutical products; and 

(b) As of the Effective Date, there are no legal claims, judgments or settlements against or owed by Relief or any of its Affiliates or
pending or, to Relief’s knowledge, threatened, in each case, relating to antitrust, anti-competition, anti-bribery or corruption violations. 

6.4. Acer Covenants. In addition to any covenants made by Acer elsewhere in this Agreement, Acer hereby covenants to Relief as
follows: 
 (a) Acer will conduct the Development Activities and Commercialization performed by it under this Agreement in a
competent and professional manner and the personnel assigned to perform Development Activities and Commercialization by Acer under this Agreement will be qualified and professionally capable of performing such Development Activities and
Commercialization; 
 (b) Acer will not knowingly, during any period in which it conducts Development, employ or use the services of
any person who is debarred or disqualified in connection with activities relating to Product; and, in the event that Acer becomes aware of the debarment or disqualification or threatened debarment or disqualification of any person providing services
to Acer with respect to any activities relating to Product, Acer will immediately notify Relief in writing and Acer will cease employing, contracting with or retaining any such person to perform any services relating to Product; 

(c) Acer will not, in connection with the performance of its obligations under this Agreement, directly or indirectly through Third
Parties, pay, promise or offer to pay, or authorize the payment of, any money or give any promise, or offer to give or authorize the giving, of anything of value to a public official or entity or other person for purpose of obtaining or retaining
business for or with, or directing business to, any person, nor will Acer directly or indirectly promise, offer or provide any corrupt payment, gratuity, emolument, bribe, kickback, illicit gift or hospitality or other illegal or unethical benefit
to a public official or entity or any other person in connection with the performance of Acer’s obligations under this Agreement; 

(d) Acer will not, in connection with the performance of its obligations under this Agreement, directly or indirectly through Third
Parties, engage in anti-competitive business practices, such as, but not limited to, price fixing, price collusion, pay-for-delay, or other anti-competitive business
practices in violation of applicable antitrust or anticompetition laws. 
 (e) Acer and its employees and contractors, in connection
with the performance of Acer’s obligations under this Agreement, will not knowingly cause Relief to be in violation of the FCPA, the Export Control Laws or any other Applicable Laws; 

(f) Acer will immediately notify Relief if it has any information or suspicion that there may be a violation of the FCPA, the Export
Control Laws or any other Applicable Laws in connection with the performance of its obligations under this Agreement; and 

  
 22 

 (g) During the Term, and except pursuant to this Agreement, neither Acer nor any of
its Affiliates, nor any of their respective licensees, assignees or successors, shall directly or indirectly seek Regulatory Approval for or Commercialize any product which is bioequivalent to Product or contains phenylbutyrate. 

6.5. Relief Covenants. In addition to any covenants made by Relief elsewhere in this Agreement, Relief hereby covenants to Acer
as follows: 
 (a) Relief will conduct the Development Activities and Commercialization performed by it under this Agreement in a
competent and professional manner and the personnel assigned to perform Development Activities and Commercialization by Relief under this Agreement will be qualified and professionally capable of performing such Development Activities and
Commercialization; 
 (b) Relief will not knowingly, during any period in which it conducts Development, employ or use the services
of any person who is debarred or disqualified in connection with activities relating to Product; and, in the event that Relief becomes aware of the debarment or disqualification or threatened debarment or disqualification of any person providing
services to Relief with respect to any activities relating to Product, Relief will immediately notify Acer in writing and Relief will cease employing, contracting with or retaining any such person to perform any services relating to Product; 

(c) Relief will not, in connection with the performance of its obligations under this Agreement, directly or indirectly through Third
Parties, pay, promise or offer to pay, or authorize the payment of, any money or give any promise, or offer to give or authorize the giving, of anything of value to a public official or entity or other person for purpose of obtaining or retaining
business for or with, or directing business to, any person, nor will Relief directly or indirectly promise, offer or provide any corrupt payment, gratuity, emolument, bribe, kickback, illicit gift or hospitality or other illegal or unethical benefit
to a public official or entity or any other person in connection with the performance of Relief’s obligations under this Agreement; 

(d) Relief will not, in connection with the performance of its obligations under this Agreement, directly or indirectly through Third
Parties, engage in anti-competitive business practices, such as, but not limited to, price fixing, price collusion, pay-for-delay, or other anti-competitive business
practices in violation of applicable antitrust or anticompetition laws. 
 (e) Relief and its employees and contractors, in
connection with the performance of Relief’s obligations under this Agreement, will not knowingly cause Acer to be in violation of the FCPA, the Export Control Laws or any other Applicable Laws; 

(f) Relief will immediately notify Acer if it has any information or suspicion that there may be a violation of the FCPA, the Export
Control Laws or any other Applicable Laws in connection with the performance of its obligations under this Agreement; 
 (g) Relief
acknowledges and agrees that Acer’s rights to the (i) BCM Patents and (ii) Subject Technology are subject to the terms, obligations and conditions of the BCM License. Relief hereby covenants to abide by the terms and conditions of the
BCM License, including Section 8.1 of the BCM License, as a condition of the Acer Sublicense, except that Relief will have no milestone or royalty payment obligations to BCM since Acer will continue to have the sole
obligation to make all milestone and royalty payments under the BCM License; and 

  
 23 

 (h) During the Term, and except pursuant to this Agreement, neither Relief nor any of
its Affiliates, nor any of their respective licensees, assignees or successors, shall directly or indirectly seek Regulatory Approval for or Commercialize any product which is bioequivalent to Product or contains phenylbutyrate. 

6.6. Performance by Affiliates and Subcontractors. The Parties recognize that each Party may perform some or all of its
obligations or exercise some or all of its rights under this Agreement through one or more Affiliates or subcontractors; provided, in each case, that (a) none of the other Party’s rights hereunder are diminished or otherwise adversely
affected as a result of such delegation or subcontracting, and (b) each such Affiliate or subcontractor undertakes in writing obligations of confidentiality and non-use regarding Confidential Information
and ownership of intellectual property rights which are substantially the same as those undertaken by the Parties pursuant to Article 8 and Article 9; and provided, further, that such Party will at all times be fully responsible for
the performance and payment of such Affiliate, subcontractor, licensee or sublicensee. 
 6.7. Disclaimer. EXCEPT AS EXPRESSLY
STATED IN THIS ARTICLE 6, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OR NON-MISAPPROPRIATION OF THIRD-PARTY INTELLECTUAL PROPERTY RIGHTS, IS MADE OR GIVEN BY OR ON BEHALF OF A PARTY. ALL SUCH REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY
EXPRESSLY EXCLUDED. Each Party understands that Product is the subject of ongoing Development and that neither Party can assure that any Product can be successfully Developed and Commercialized. 

ARTICLE 7 

INDEMNIFICATION; LIMITATION OF LIABILITY 

7.1. Indemnification by Relief. Relief hereby agrees to defend, hold harmless and indemnify each of Acer, its Affiliates and
their agents, shareholders, directors, officers, employees and consultants and successors and assigns of any of the foregoing (the “Acer Indemnitees”) from and against any and all liabilities, expenses and losses, including
reasonable legal expenses and attorneys’ fees (collectively “Losses”), incurred by any Acer Indemnitee as a result of any suits, claims, actions and demands brought by a Third Party (each, a “Third Party
Claim”) arising directly or indirectly out of (a) any breach of any representations, warranties, covenants or agreements by Relief under this Agreement (including a breach of the BCM License), (b) the negligence or willful misconduct
of any Relief Indemnitee or (c) the research, Development, manufacture, use, handling, storage, Commercialization or other disposition of Product by Relief or any of its Affiliates, or any of their respective licensees, assignees or successors.
Relief’s obligation to indemnify the Acer Indemnitees pursuant to the foregoing sentence will not apply to the extent that any such Losses arise from any activities set forth in Section 7.2 for which Acer is obligated to indemnify
Relief Indemnitees under Section 7.2. Furthermore, Relief hereby agrees to indemnify the HHMI Indemnitees (as defined in the BCM License) by counsel reasonably acceptable to HHMI (as defined in the BCM License) and to hold
the HHMI Indemnitees harmless from and against any HHMI Claims (as defined in the BCM License) based upon arising out of or otherwise relating to the BCM License or this Agreement, including any cause of action relating to product liability, or the
use, handling, storage or disposition of Product and Acer Technology by Relief or others who possess Product and Acer Technology through a chain of possession leading back, directly or indirectly, to Relief. The previous sentence will not apply to
any HHMI Claim that is determined with finality by a court of competent jurisdiction to result solely from the gross negligence or willful misconduct of an HHMI Indemnitee. Relief further agrees not to settle any HHMI Claim against an HHMI
Indemnitee without HHMI’s written consent where (i) such settlement would include any admission of liability on the part of any HHMI Indemnitee, (ii) such settlement would impose any restriction on any HHMI Indemnitee’s conduct
of any of its activities or (iii) such settlement would not include an unconditional release of all HHMI Indemnitees from all liability for claims that are the subject matter of the settled claim. 

  
 24 

 7.2. Indemnification by Acer. Acer hereby agrees to defend, hold harmless and
indemnify Relief, its Affiliates and their agents, shareholders, directors, officers, employees and consultants and successors and assigns of any of the foregoing (the “Relief Indemnitees”) from and against any and all Losses
incurred by any Relief Indemnitee as a result of any Third Party Claims arising directly or indirectly out of (a) any breach of any representations, warranties, covenants or agreements by Acer under this Agreement, (b) the negligence or
willful misconduct of any Acer Indemnitee or (c) the research, Development, manufacture, use, handling, storage, Commercialization or other disposition of Product by Acer or any of its Affiliates, or any of their respective licensees, assignees
or successors. Acer’s obligation to indemnify the Relief Indemnitees pursuant to the foregoing sentence will not apply to the extent that any such Losses arise from any activities set forth in Section 7.1 for which
Relief is obligated to indemnify Acer Indemnitees under Section 7.1. 
 7.3. Procedure. The
indemnified Party will provide the indemnifying Party with prompt notice of the claim giving rise to the indemnification obligation pursuant to this Article 7 and the exclusive ability to defend (with the reasonable cooperation of the
indemnified Party) or settle any such claim; provided, however, that the indemnifying Party will not enter into any settlement for damages other than monetary damages without the indemnified Party’s written consent, such consent not to
be unreasonably withheld. The indemnified Party will have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the indemnifying Party. If the Parties cannot agree
as to the application of Sections 7.1 and 7.2 to any particular Third-Party Claim, the Parties may conduct separate defenses of such Third Party Claim. Each Party reserves the right to claim indemnity from the other in accordance with
Sections 7.1 and 7.2 above upon resolution of the underlying claim, notwithstanding the provisions of this Section 7.3 requiring the indemnified Party to tender to the indemnifying Party the exclusive ability
to defend such claim or suit. The failure to deliver written notice to the indemnifying Party within a reasonable time after the commencement of any action with respect to a Third Party Claim will only relieve the indemnifying Party of its
indemnification obligations under this Article 7 if and to the extent the indemnifying Party is actually prejudiced thereby. 

7.4. Limitation of Liability. NEITHER PARTY WILL BE LIABLE TO THE OTHER FOR ANY SPECIAL, INCIDENTAL, PUNITIVE OR INDIRECT
DAMAGES OR LOSS OF PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 7.4 IS INTENDED TO OR WILL LIMIT OR
RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 7.1 OR 7.2, OR DAMAGES AVAILABLE FOR A PARTY’S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE 8. 

  
 25 

 7.5. Insurance. Each Party, at its own expense, will maintain product
liability and other appropriate insurance (or self-insure) in an amount consistent with sound business practice in the region(s) where the Party operates and reasonable in light of its obligations under this Agreement. Each Party will provide a
certificate of insurance (or evidence of self-insurance) evidencing such coverage to the other Party upon request. 
 ARTICLE 8 

CONFIDENTIALITY 

8.1. Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties,
each Party (in such capacity, the “Receiving Party”) agrees that, for the Term and for a period of ten (10) years thereafter, it will keep confidential and will not publish or otherwise disclose and will not use for any purpose
other than as provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder) any Confidential Information of the other Party (in such capacity, the “Disclosing Party”).
Pursuant to Section 9.1, all Development Data shall be deemed as Confidential Information of Acer. The Receiving Party will use at least the same standard of care as it uses to protect proprietary or confidential
information of its own (but in no event less than reasonable care) to ensure that its, and its Affiliates’, employees, directors, officers, agents, consultants, advisors (including legal, accounting or other professional advisors) and other
representatives (collectively the “Representatives”) do not disclose or make any unauthorized use of the Confidential Information. The Receiving Party may disclose Confidential Information only to its Representatives on a need-to-know basis, and the Receiving Party shall have executed appropriate written agreements with its Representatives sufficient to enable it to comply with all the
provisions of this Agreement, and the Receiving Party will be responsible for the acts or omissions of such Representatives with regards to any breach of the confidentiality obligations herein by such Representatives. The Receiving Party will
promptly notify the Disclosing Party upon discovery of any unauthorized use or disclosure of the Disclosing Party’s Confidential Information and will cooperate with the Disclosing Party in every reasonable way to help the Disclosing Party
regain possession of the Confidential Information and prevent its further unauthorized use or disclosure. The foregoing confidentiality and non-use obligations will not apply to any portion of the Confidential
Information that the Receiving Party can demonstrate by competent written proof: 
 (a) was already known to the Receiving Party,
other than under an obligation of confidentiality, at the time of disclosure by the Disclosing Party; 
 (b) was generally available
to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party; 

  
 26 

 (c) became generally available to the public or otherwise part of the public domain
after its disclosure and other than through any act or omission of the Receiving Party in breach of this Agreement; 
 (d) is
subsequently disclosed to the Receiving Party by a Third Party who has a legal right to make such disclosure without any obligation of confidentiality; or 

(e) is subsequently independently discovered or developed by the Receiving Party without the aid, application or use of the Disclosing
Party’s Confidential Information, as evidenced by written records. 
 8.2. Authorized Disclosure. Notwithstanding the
obligations set forth in Section 8.1, the Receiving Party may disclose the Disclosing Party’s Confidential Information and the terms of this Agreement to the extent: 

(a) such disclosure is reasonably necessary for (i) Development or Commercialization or manufacture or supply of any Product,
including obtaining and maintaining Regulatory Approval or patent protection, pursuant to the terms of this Agreement; or (ii) prosecuting or defending litigation as contemplated by this Agreement; 

(b) such disclosure is reasonably necessary: (i) to the Receiving Party’s directors, attorneys, independent accountants or
financial advisors for the sole purpose of enabling such directors, attorneys, independent accountants or financial advisors to provide advice to the Receiving Party, provided, that in each such case on the condition that such directors,
attorneys, independent accountants and financial advisors are bound in writing by confidentiality and non-use obligations consistent with those contained in this Agreement; or (ii) to actual or potential
investors, acquirers, licensors, licensees, collaborators or other business partners solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition, license or collaboration; provided that in each such case on
the condition that such disclosures are bound in writing by confidentiality and non-use obligations consistent with those contained in this Agreement; or 

(c) such disclosure is required by Applicable Laws, including judicial or administrative process. Confidential Information that is
disclosed under this Section 8.2(c) will remain otherwise subject to the confidentiality and non-use provisions of this Article 8, and the Party disclosing Confidential
Information pursuant to Applicable Laws may disclose, but only to the extent so required, and will take all steps reasonably necessary, including seeking of confidential treatment or a protective order to ensure the continued confidential treatment
of such Confidential Information. 
 Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party’s
Confidential Information pursuant to Section 8.2(a)(ii) or Section 8.2(c), it will give reasonable advance written notice to the other Party of such disclosure to allow the other Party a reasonable
opportunity to seek a protective order or equivalent and use efforts to secure confidential treatment of such information at least as diligent as such Party would use to protect its own confidential information, but in no event less than reasonable
efforts. In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential Information hereunder. Any such disclosure, however, will not relieve such Party of its obligations as the Receiving Party contained herein.

  
 27 

 8.3. Public Announcements. 

(a) Publicity. Subject to the rest of this Section 8.3, no Party will use the name, trademark, trade
name or logo of the other Party, its Affiliates or their respective employee(s) in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other
Party, except as may be required by Applicable Laws. 
 (b) Press Releases. As soon as practicable following the Effective
Date, the Parties will issue a joint press release announcing the execution of this Agreement in substantially the form exchanged between and agreed to by the Parties prior to the Effective Date. Except as required by applicable securities laws
(including disclosure requirements of the U.S. Securities and Exchange Commission (“SEC”) or any stock exchange on which securities issued by a Party or its Affiliates are traded), neither Party will make any other public
announcement concerning this Agreement or the subject matter hereof without the prior written consent of the other, which will not be unreasonably withheld or delayed; provided that each Party may make any public statement in response to
questions by the press, analysts, investors or those attending industry conferences or financial analyst calls, or issue press releases, so long as any such public statement or press release is not inconsistent with prior public disclosures or
public statements approved by the other Party pursuant to this Section 8.3 and which do not reveal non-public information about the other Party. In the event of a required public
announcement, to the extent practicable under the circumstances, the Party making such announcement will provide the other Party with a copy of the proposed text of such announcement sufficiently in advance of the scheduled release to afford such
other Party a reasonable opportunity to review and comment upon the proposed text. 
 (c) Filing of this Agreement. The
Parties will coordinate in advance with each other in connection with the filing of this Agreement (including redaction of certain provisions of this Agreement) with the SEC or any stock exchange or governmental agency on which securities issued by
a Party or its Affiliate are traded, and each Party will use reasonable efforts to seek confidential treatment for the terms proposed to be redacted; provided, that each Party will ultimately retain control over what information to disclose
to the SEC or any stock exchange or other governmental agency, as the case may be, and provided, further, that the Parties will use their reasonable efforts to file redacted versions with any governing bodies which are consistent with
redacted versions previously filed with any other governing bodies. Other than such obligation, neither Party (nor its Affiliates) will be obligated to consult with or obtain approval from the other Party with respect to any filings to the SEC or
any stock exchange or other governmental agency. 
 8.4. Publication. At least thirty (30) days prior to a Party or of
any of its Affiliates publishing, publicly presenting or submitting for written or oral publication a manuscript, abstract or the like that includes Acer Technology that has not been previously published, such Party will provide to the other Party a
draft copy thereof for its review (unless such Party is required by law to publish such Acer Technology sooner, in which case such Party will provide such draft copy to the other Party as much in advance of such publication as possible). The
publishing Party will consider in good faith any comments provided by the other Party during such thirty (30) day period. The review period may be extended for an additional sixty (60) days if a representative of the non-publishing Party can demonstrate a reasonable need for such extension (including the preparation and filing of patent applications). By mutual agreement of the Parties, this period may be further extended. In
addition, the publishing Party shall, and will cause its Affiliates to, as applicable, at the other Party’s reasonable request, remove therefrom any Confidential Information of such other Party. The contribution of each Party will be noted in
all publications or presentations by acknowledgment or co-authorship, whichever is appropriate. 

  
 28 

 8.5. Prior Non-Disclosure Agreement.
As of and from the Effective Date, the terms of this Article 8 will supersede any prior non-disclosure, secrecy or confidentiality agreement between the Parties (or their Affiliates) dealing with the
subject of this Agreement. Any information disclosed pursuant to any such prior agreement will be deemed Confidential Information for purposes of this Agreement. 

8.6. Equitable Relief. Each Party acknowledges that a breach of this Article 8 cannot be reasonably or adequately
compensated in damages in an action at law and that such a breach will cause the other Party irreparable injury and damage. By reason thereof, each Party agrees that the other Party will be entitled, in addition to any other remedies it may have
under this Agreement or otherwise, to seek preliminary and permanent injunctive and other equitable relief to prevent or curtail any breach of the obligations relating to Confidential Information set forth herein. 

ARTICLE 9 
 INTELLECTUAL
PROPERTY 
 9.1. Ownership. For avoidance of doubt, as between the Parties and subject to the Acer Technology License and
the Acer Sublicense, Acer is the sole owner of all rights, title and interest in and to all Acer Patents, Acer Know-How and Development Data, and all intellectual property rights (including patent, copyright,
trade secret and application of patent) therein, including any and all existing or future rights, whether patentable or not. Relief agrees and hereby irrevocably transfers and assigns to Acer any and all such rights, title and interest, and will
perform and, if necessary, obligate its personnel to perform any and all other reasonable acts necessary to assist Acer in obtaining, maintaining, implementing, securing and perfecting any and all such rights, title and interest, including executing
the necessary documents by Relief or its personnel. 
 9.2. Acer License Grants. 

(a) Subject to the terms and conditions of this Agreement, and excluding any BCM Patents or Subject Technology therein, Acer hereby
grants an exclusive (even with respect to Acer except as necessary or appropriate for Acer to perform its obligations under the Clinical Supply and Quality Agreement, the Commercial Supply and Quality Agreement, the Pharmacovigilance Agreement and
any other agreements or arrangements similar to the foregoing or otherwise providing for the manufacture or supply of Product), nontransferable, sublicensable (with prior written notice to Acer) license to Relief under the Acer Patents (to the
extent within the Relief Territory), Acer Know-How and Development Data for Development and Commercialization in the Field in the Relief Territory (the “Acer Technology License”). 

  
 29 

 (b) Subject to the terms and conditions of this Agreement and the BCM License
(including Section 8.1 thereof), Acer hereby grants a non-sublicensable sublicense to Relief under the BCM Patents (to the extent within the Relief Territory) and Subject Technology
for Development and Commercialization in the Field in the Relief Territory (the “Acer Sublicense”). 
 9.3.
Rights to Improvements and Independent Inventions. 
 (a) Improvements shall be automatically included as part of the Acer Know-How and, to the extent Improvements result in applications for patents, whether patentable or not, shall be automatically included as part of the Acer Patents. Each Party agrees to use reasonable efforts to
disclose to the other Party any and all Improvements and to promptly update Exhibit A attached hereto from time to time, as may be requested by either Party in writing, to reflect the inclusion of any Improvements in the Acer Patents. 

(b) Subject to the rights granted to Relief in Section 9.2, Acer shall own all right, title and interest in
and to all Improvements. Relief agrees and hereby irrevocably transfers and assigns to Acer any and all such rights, title and interest in and to all Improvements, and will perform and, if necessary, obligate its personnel to perform any and all
other reasonable acts necessary to assist Acer in obtaining, maintaining, implementing, securing and perfecting any and all such rights, title and interest, including executing the necessary documents by Relief or its personnel. 

(c) Relief shall own all right, title and interest in and to all Independent Inventions invented, developed, created, or reduced to
practice by or on behalf of Relief. 
 (d) Relief hereby grants a non-exclusive,
transferable, sublicensable, perpetual, irrevocable, fully paid-up worldwide license to Acer under the Independent Inventions for Development and Commercialization in the Field. Notwithstanding any provision
herein to the contrary, such license shall survive any expiration or termination of this Agreement. 
 9.4. Prosecution and
Maintenance of Patent Rights. 
 (a) For the Term, Acer will be responsible for filing, prosecuting and maintaining all patent
applications and patents included in the Patent Rights, whether in the Acer Territory or the Relief Territory, using independent patent counsel reasonably acceptable to Relief in the Relief Territory. Acer will at Relief’s expense (subject to
Section 9.3(b)): (i) instruct such patent counsel to furnish Relief with copies of all material correspondence relating to the Patent Rights from the United States Patent and Trademark Office (USPTO) and any other patent
office, as well as copies of all proposed responses to such material correspondence in time for Relief to review and comment on such response; (ii) give Relief an opportunity to review the text of each patent application before filing;
(iii) consult with Relief with respect thereto; (iv) supply Relief with a copy of the application as filed, together with notice of its filing date and serial number; and (v) keep Relief advised of the status of actual and prospective
patent filings. Acer will give Relief the opportunity to provide comments on and make requests of Acer concerning the preparation, filing, prosecution, protection and maintenance of the Patent Rights, and will consider such comments and requests in
good faith. Subject to Section 9.3(b), Relief agrees to pay all documented, out-of-pocket legal costs, expenses and filing fees with respect to
the foregoing activities in the Relief Territory. Acer will instruct patent counsel to invoice Relief directly for all such out-of-pocket legal costs, expenses and
filing fees, and Relief agrees to pay all such undisputed invoices within thirty (30) days of receipt. 

  
 30 

 (b) In the event that Relief decides not to pay for the costs associated with either

 (i) the prosecution of any of the Patent Rights in any country in the Relief Territory to issuance or 

(ii) maintenance of any foreign issued patent on the Patent Rights in the Relief Territory, Relief will timely notify Acer in writing thereof
(such Patent Rights in such country will be referred to as “Abandoned Patent Rights”). In the event of Relief’s abandonment of any Patent Rights in any country, the Acer Technology License or the Acer Sublicense, as applicable,
will terminate with respect to such Abandoned Patent Rights. 
 9.5. Infringement by Third Parties. During the Term, each
Party will promptly inform the other of any infringement of any claims in the Acer Technology or the misuse, misappropriation, theft or breach of confidence of other proprietary rights in the Acer Technology or any Development Data by a Third Party
(“Infringement”). Any action or proceeding will be instituted as following (where Acer is the “First Party” in the Acer Territory and the “Second Party” in the Relief Territory and Relief is the
“First Party” in the Relief Territory and the “Second Party” in the Acer Territory): 
 (a) Suit
by the First Party. The First Party will have the first right, but not the obligation, to take action in the prosecution, prevention or termination of any Infringement. Before the First Party commences an action with respect to any Infringement,
the First Party will consider in good faith the views of the Second Party in making its decision whether to sue. Should the First Party elect to bring suit, the First Party will keep the Second Party reasonably informed of the progress of the action
and will give the Second Party a reasonable opportunity in advance to consult with the First Party and offer its views about major decisions affecting the litigation. The First Party will give careful consideration to those views, but will have the
right to control the action. Should the First Party elect to bring suit and the Second Party is joined as party plaintiff in any such suit, the Second Party will have the right to approve the counsel selected by the First Party to represent the
Parties, such approval not to be unreasonably withheld. The expenses of such suit or suits that the First Party elects to bring, including any expenses of the Second Party incurred in conjunction with the prosecution of such suits or the settlement
thereof, will be paid for entirely by the First Party and the First Party will hold the Second Party free, clear and harmless from and against any and all costs of such litigation, including reasonable attorneys’ fees. The First Party will not
compromise or settle such litigation without the prior written consent of the Second Party, which consent will not be unreasonably withheld or delayed. In the event the First Party exercises its right to sue pursuant to this
Section 9.5(a), it will first reimburse itself out of any sums recovered in such suit or in settlement thereof for all costs and expenses of every kind and character, including reasonable attorneys’ fees, necessarily
incurred in the prosecution of any such suit. If, after such reimbursement, any funds remain from said recovery, then such funds shall be treated as Net Sales. The Second Party will exercise reasonable cooperation in connection with the First
Party’s action with respect to Infringement under this Section 9.5(a). 

  
 31 

 (b) Suit by the Second Party. If the First Party does not take action in the
prosecution, prevention or termination of any Infringement pursuant to Section 9.5(b) above, and has not commenced negotiations with the infringer for the discontinuance of said Infringement, within one-hundred and eighty (180) calendar days after the Parties being made aware of the existence of an Infringement, the Second Party may elect to do so. Should the Second Party elect to bring suit and the First
Party is joined as party plaintiff in any such suit, the First Party will have the right to approve the counsel selected by the Second Party to represent the Parties, such approval not to be unreasonably withheld. The expenses of such suit or suits
that the Second Party elects to bring, including any expenses of the First Party incurred in conjunction with the prosecution of such suits or the settlement thereof, will be paid for entirely by the Second Party and the Second Party will hold the
First Party free, clear and harmless from and against any and all costs of such litigation, including reasonable attorneys’ fees. The Second Party will not compromise or settle such litigation without the prior written consent of the First
Party, which consent will not be unreasonably withheld or delayed. In the event the Second Party exercises its right to sue pursuant to this Section 9.5(b), it will first reimburse itself out of any sums recovered in such
suit or in settlement thereof for all costs and expenses of every kind and character, including reasonable attorneys’ fees, necessarily incurred in the prosecution of any such suit. If, after such reimbursement, any funds remain from said
recovery, then such funds shall be treated as Net Sales. The First Party will exercise reasonable cooperation in connection with the Second Party’s action with respect to Infringement under this Section 9.5(b). 

9.6. No Implied Licenses. No right or license is granted under this Agreement by either Party to the other Party, either
expressly or by implication, except those specifically set forth herein. 
 ARTICLE 10 

TERM AND TERMINATION 

10.1. Term. This Agreement will become effective on the Effective Date and, unless earlier terminated pursuant to this
Article 10, will remain in effect until the later of (a) the date that the Parties cease Development and Commercialization of Product in a Territory pursuant to this Agreement; or (b) the expiration of all payment obligations of the
Parties under Section 5 (the “Term”). 
 10.2. Termination for Breach. Each Party
will have the right to terminate this Agreement in its entirety immediately upon written notice to the other Party, if the other Party materially breaches its obligations under this Agreement and, after receiving written notice identifying such
material breach in reasonable detail, such breaching party fails to cure such material breach within sixty (60) days (or fifteen (15) days with respect to any payment breach) from the date of such notice. Any right to terminate under this
Section 10.2, other than with respect to any payment breach, will be stayed and the cure period tolled in the event that, during any cure period, the Party alleged to have been in material breach initiates dispute
resolution in accordance with Article 11 with respect to the alleged breach, which stay and tolling will continue until such dispute has been resolved in accordance with Article 11. 

  
 32 

 10.3. Termination for Good Reason. Either Party will have the right to
terminate this Agreement upon written notice to the other Party if the terminating Party reasonably determines, based upon additional information that becomes available or an analysis of the existing information at any time, that the medical
risk/benefit of Product is so unfavorable that it would be incompatible with the welfare of patients to Develop or Commercialize or to continue to Develop or Commercialize Product. Prior to any such termination, the terminating Party will comply
with such internal review and management approval processes as it would normally follow in connection with the termination of the development and commercialization of its own products for safety reasons and will present and discuss the findings of
such internal review for approval by the Executive Officers. 
 10.4. Termination for Bankruptcy. Each Party will have the
right to terminate this Agreement in its entirety immediately upon written notice to the other Party, if the other Party files in any court or agency, pursuant to any statute or regulation of any state or country, a petition in bankruptcy or
insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of such other Party or of substantially all of its assets, or if such other Party proposes a written agreement of composition or extension of
substantially all of its debts, or if such other Party is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition is not be dismissed within ninety (90) days after the filing thereof, or if such
other Party proposes or is a party to any dissolution or liquidation, or if such other Party makes an assignment of substantially all of its assets for the benefit of creditors. 

10.5. Relief Termination. This Agreement will terminate in connection with a Relief Termination as described in
Section 3.3(a). 
 10.6. Effect of Termination 

(a) Development Data. If this Agreement is terminated for any reason, Relief shall, for a period of ninety (90) days
following the effective date of such termination, provide Acer access to and transfer all Development Data in its possession to Acer as of the effective date of such termination. 

(b) Development Activities. If this Agreement is terminated for any reason, then: (i) notwithstanding anything to the
contrary herein, Acer will have the sole right to continue Development and Commercialization; and (ii) Relief will wind-down any of its ongoing Development and Commercialization activities in an orderly fashion, except as otherwise agreed to in
any agreement entered into between the Parties. 
 (c) Confidential Information. Upon expiration or termination of this
Agreement in its entirety, and with acknowledgement that all Development Data shall be solely owned by Acer as provided in Section 8.1, each Party shall, subject to the sole discretion and option of the other Party owning
the Confidential Information or the Development Data, promptly return to the other Party, or delete or destroy, all relevant records and materials in such Party’s possession or control containing Confidential Information (including Development
Data) of the other Party; provided that such Party may keep one copy of such materials for archival purposes only subject to continuing confidentiality obligations. 

  
 33 

 (d) Payment Obligations. In the event of any expiration or termination of this
Agreement, any accrued payment obligations will survive such termination until fully paid. Except in the event of termination by Relief due to Sections 10.2 or 10.4, Acer will have the right to receive, and Relief will have the
obligation to pay, all Royalty Payments, the Reimbursement Payment, the Milestone Payments and the Development Payments due to Acer under Sections 5.2 and 5.3 and accruing as of the date of termination, which sections will survive
expiration or termination of this Agreement. Except in the event of termination by Acer due to Sections 10.2 or 10.4, Relief will have the right to receive, and Acer will have the obligation to pay, all Profit Sharing Payments due to
Relief under Section 5.4, which section will survive expiration or termination of this Agreement. 
 10.7.
Survival. Expiration or termination of this Agreement will not relieve either Party of any obligation or liability accruing prior to such expiration or termination, nor will expiration or any termination of this Agreement preclude either
Party from pursuing all rights and remedies it may have under this Agreement, at law or in equity, with respect to breach of this Agreement. Without limiting the foregoing, the following provisions, including the Parties’ rights and obligations
thereunder, will survive any expiration or termination of this Agreement: Articles 1, 7, 8, 11, 12 and Sections 9.1, 9.3, 10.6 and 10.7 and those which, by their nature, are intended to survive. 

ARTICLE 11 
 DISPUTE
RESOLUTION 
 11.1. Disputes. The Parties recognize that disputes as to certain matters may from time to time arise during
the Term which relate to either Party’s rights or obligations hereunder. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner by mutual
cooperation and without resort to litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Article 11 to resolve any controversy or claim arising out of, relating to or in connection with any
provision of this Agreement, if and when a dispute arises under this Agreement. 
 11.2. Dispute Resolution. In the event that
a dispute arises between the Parties in the course of this Agreement, the dispute will be referred to the attention of the President of Relief and the President of Acer or their designees (the “Executive Officers”). The Executive
Officers will meet as soon as reasonably possible thereafter and in good faith attempt to resolve such dispute. If, within thirty (30) days after referral of such dispute to the Executive Officers by either Party, the Executive Officers are
unable to resolve such dispute, either Party will have the right to have the dispute resolved by binding arbitration, initiated by either Party on ten (10) Business Days’ notice to the other Party following the expiration of the thirty
(30) day period referenced above (the “Initiation Notice”), under the Commercial Arbitration Rules of the American Arbitration Association (“AAA”) then pertaining (available at www.adr.org), except where those
rules conflict with this provision, in which case this provision controls, applying the laws of the State of New York, without regards to its conflicts of law provisions, before three (3) independent, neutral arbitrators experienced in the
pharmaceutical industry and licensing transactions in such industry. The place of arbitration will be New York, New York. Relief and Acer will each be entitled to select one (1) such arbitrator, with the two (2) such arbitrators so
selected selecting the third (3rd) such arbitrator. In the event either Party fails to select its arbitrator within ten (10) Business Days of the Initiation Notice, the arbitrator selected by the other Party within such ten (10) Business
Day period will be entitled to select such arbitrator. The arbitration will be conducted in English. The decision of the arbitrators will be final and binding on the Parties, and any decision of the arbitrators may be enforced in any court of
competent jurisdiction. Each Party will bear its own expenses and an equal share of the reasonable, documented expenses of the arbitration panel and any fees required by AAA to submit such matter to arbitration, unless the panel determines that any
such fees or expenses are to be paid by the non-prevailing Party. Notwithstanding the foregoing, either Party may seek injunctive, equitable or similar relief from a court of competent jurisdiction as
necessary to enforce its rights hereunder without the requirement of arbitration. 

  
 34 

 ARTICLE 12 

MISCELLANEOUS 

12.1. Entire Agreement; Amendment. This Agreement, including the Exhibits attached hereto, sets forth the complete, final and
exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with respect to the subject matter hereof and supersedes, as of the Effective Date, all prior
agreements and understandings between the Parties with respect to the subject matter hereof. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other
than as are set forth herein and therein. No subsequent alteration, amendment, change or addition to this Agreement will be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party. 

12.2. Force Majeure. Each Party will be excused from the performance of its obligations under this Agreement, other than
obligations to make payments when due, to the extent that such performance is prevented by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse will be continued so long as the
condition constituting force majeure continues, the nonperforming Party takes reasonable efforts to remove the condition and provided that the nonperforming Party has not caused such condition to occur. For purposes of this Agreement, force
majeure will include conditions beyond the reasonable control of the nonperforming Party, including an act of God, domestic or international terrorism, involuntary compliance with any regulation, law or order of any government, war, civil commotion,
epidemic, pandemic, failure or default of public utilities, Internet providers or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe. If a force majeure persists for more than ninety
(90) days, then the Parties will discuss in good faith the modification of the Parties’ obligations under this Agreement in order to mitigate the delays caused by such force majeure. 

12.3. Bankruptcy Code. All licenses and rights granted under this Agreement will be deemed licenses of rights to intellectual
property for purposes of Section 365(n) of the United States Bankruptcy Code or any analogous provisions in any other country or jurisdiction and a licensee or sublicensee under this Agreement will retain and may fully exercise all of its
rights and elections under the United States Bankruptcy Code or any analogous provisions in any other country or jurisdiction. 

  
 35 

 12.4. Notices. Any notice required or permitted to be given under this
Agreement will be in writing, will specifically refer to this Agreement, and will be delivered either in person, by any method of mail (postage prepaid) requiring return receipt, or by reputable overnight courier or email confirmed thereafter by any
of the foregoing, to the Party to be notified at the address specified below or such other address as may be specified by such Party in writing in accordance with this Section 12.4. Notice will be deemed to have been
sufficiently given for all purposes upon the earliest of (a) the date of actual receipt, if hand-delivered, or sent by email with electronic confirmation of receipt, or a reputable courier service, or (b) five (5) Business Days after
mailing, if mailed by first class certified or registered airmail, postage prepaid, return receipt requested. 
  

			
	 If to Relief:
	  	 Relief Therapeutics
 Batiment F2/F3

Avenue de Secheron 15
 1202 Geneve, Switzerland

ATTN: Jeremy Meinen

Email: jeremy.meinen@relieftherapeutics.com

		
	 If to Acer:
	  	 Acer Therapeutics Inc.
 One Gateway Center

300 Washington Street, Suite 351
 Newton, MA 02458

ATTN: Chris Schelling, President & CEO
 Email:
cschelling@acertx.com
  

With a copy (which will not constitute notice) to:

Acer Therapeutics Inc.
 One Gateway Center

300 Washington Street, Suite 351
 Newton, MA 02458

ATTN: Don Joseph, Chief Legal Officer
 Email:
djoseph@acertx.com

 12.5. No Strict Construction; Headings. This Agreement has been prepared jointly and will not be
strictly construed against either Party. Ambiguities, if any, in this Agreement will not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. The headings of each Article and Section in
this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Article or Section. 

12.6. Assignment. Neither Party will assign this Agreement without the prior written consent of the other Party, provided,
however, that (i) a Party is permitted to assign this Agreement without such consent in connection with the transfer or sale of all or substantially all of its assets, capital stock or business related to this Agreement, or in the event of
its merger or consolidation or change in control, corporate recapitalization or restructuring or similar transaction, and (ii) a Party is permitted to assign or transfer to, or otherwise monetize any portion of its economic benefits with,
lenders or investors for financing purposes. Any permitted successor or assignee of obligations hereunder shall, in writing to the other Party, expressly assume performance of such obligations. Any permitted assignment will be binding on the
successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the foregoing will be null, void and of no legal effect. 

  
 36 

 12.7. Further Actions. Each Party agrees to execute, acknowledge and deliver
such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

12.8. No Third Party Beneficiaries. This Agreement is neither expressly nor impliedly made for the benefit of any party other
than those executing it, except as expressly provided with respect to the Acer Indemnitees and the Relief Indemnitees. 
 12.9.
Severability. If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision will be considered severed from this
Agreement and will not serve to invalidate any remaining provisions hereof. The Parties will make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the
Parties when entering this Agreement may be realized. 
 12.10. No Waiver. Any delay in enforcing a Party’s rights under
this Agreement or any waiver as to a particular default or other matter will not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, except with respect to an express written and signed
waiver relating to a particular matter for a particular period of time. 
 12.11. Independent Contractors. Each Party will act
solely as an independent contractor, and nothing in this Agreement will be construed to give either Party the power or authority to act for, bind, or commit the other Party in any way. Nothing herein will be construed to create the relationship of
partners, principal and agent, or joint-venture partners between the Parties. 
 12.12. Interpretations. In this Agreement,
unless otherwise specified: 
 (a) “includes” and “including” mean, respectively, “includes without
limitation” and “including without limitation;” 
 (b) the word “or” means “and/or” unless the
context dictates otherwise because the subject of the conjunction is mutually exclusive; 
 (c) words denoting the singular will
include the plural and vice versa and words denoting any gender will include all genders; 
 (d) words such as “herein,”
“hereof” and “hereunder” refer to this Agreement as a whole and not merely to the particular provision in which such words appear; 

(e) all references to days, quarters and years in this Agreement mean calendar days, quarters and years, respectively, unless otherwise
specified; and 
 (f) the Exhibits attached hereto form part of the operative provision of this Agreement and references to this
Agreement will include references to such Exhibits. 

  
 37 

 12.13. English Language. This Agreement was prepared in the English language,
which language will govern the interpretation of, and any dispute regarding, the terms of this Agreement. To the extent this Agreement requires a Party to provide to the other Party information, correspondence, notice or other documentation, such
Party will provide such information, correspondence, notice or other documentation in the English language and also a copy of the original of such information, correspondence, notice or other documentation if such original is not in the English
language. 
 12.14. Governing Law. This Agreement and all disputes arising out of or related to this Agreement or any breach
hereof will be governed by and construed under the laws of State of New York, U.S., without giving effect to any choice of law principles that would require the application of the laws of a different jurisdiction and excluding the United Nations
Convention on Contracts for the International Sales of Goods. 
 12.15. Counterparts. This Agreement may be executed in two
(2) or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. Facsimile and other electronically scanned signatures shall have the same effect as their originals. 

  
 38 

 Confidential 

IN WITNESS WHEREOF, the Parties have caused their duly authorized representatives to execute this Collaboration and License Agreement
as of the Effective Date. 
  

									
	ACER THERAPEUTICS INC.	 		 	RELIEF THERAPEUTICS HOLDING AG
					
	By:	 	/s/ Chris Schelling	 		 	By:	 	/s/ Tom Plitz
	Name:	 	Chris Schelling	 		 	Name:	 	Tom Plitz
	Title:	 	CEO and Founder	 		 	Title:	 	Member, Board of Directors

 Exhibit A 

Acer Patents 
 TITLE: PALATABLE
COMPOSITIONS INCLUDING SODIUM PHENYLBUTYRATE AND USES THEREOF 
  

											
	 Country
	  	 Application

Type
	  	 Status
	  	 Serial No.
	  	 Filing Date
	  	 Publication No.

	AU — Australia	  	National Stage	  	Published	  	2016398029	  	10/17/2016	  	2016398029
	BH — Bahrain	  	National Stage	  	Pending	  	166/2018	  	10/17/2016	  	
	EP — Europe	  	National Stage	  	Published	  	16894786.9	  	10/17/2016	  	3429559
	IL — Israel	  	National Stage	  	Published	  	261777	  	10/17/2016	  	261777
	KR — South Korea	  	National Stage	  	Published	  	10-2018-7029452	  	10/17/2016	  	20190008840A
	KW — Kuwait	  	National Stage	  	Pending	  	PCT/139/2018	  	10/17/2016	  	
	MX — Mexico	  	National Stage	  	Published	  	MX/a2018/011229	  	10/17/2016	  	MX/a2018/011229
	NZ — New Zealand	  	National Stage	  	Pending	  	746866	  	10/17/2016	  	
	OM — Oman	  	National Stage	  	Pending	  	OM/P/2018/00274	  	10/17/2016	  	
	QA — Qatar	  	National Stage	  	Pending	  	QA/201809/00400	  	10/17/2016	  	
	SA — Saudi Arabia	  	National Stage	  	Pending	  	518400020	  	10/17/2016	  	
	SG — Singapore	  	National Stage	  	Abandoned	  	11201807979S	  	10/17/2016	  	
	AE — United Arab Emirates	  	National Stage	  	Pending	  	P6001296/2018	  	10/17/2016	  	
	WO — Patent Cooperation Treaty	  	PCT	  	National Phase	  	PCT/US2016/057415	  	10/17/2016	  	WO 2017/160345

 TITLE: ADMINISTRATION OF SODIUM PHENYLBUTYRATE IN A FASTED
STATE TO TREAT UREA CYCLE DISORDERS 
  

											
	 Country
	  	 Application

Type
	  	 Status
	  	 Serial No.
	  	 Filing Date
	  	 Publication No.

	US — United States	  	Provisional	  	Pending	  	63/048,892	  	7/7/2020	  	
	US — United States	  	Provisional	  	Pending	  	63/065,272	  	8/13/2020	  	

 Exhibit B 

BCM Patents 
  

															
	 Appl. No.
	  	Appl.
Date	  	Matter No.	  	 Title
	  	 Case Status
(Internal)
	  	Reg. No.	  	Reg. Date	  	 Country

	10803013.1	  	7/26/2010	  	1000340505	  	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	  	Issued	  	2456304	  	8/19/2015	  	Austria
	10803013.1	  	7/26/2010	  	
	10803013.1	  		  	1000208589	  	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	  	Issued	  	2456304	  	8/19/2015	  	Switzerland
	10803013.1	  	7/26/2010	  	1000208588	  	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	  	Issued	  	2456304	  	8/19/2015	  	Germany
	10803013.1	  	7/26/2010
	10803013.1	  		  	1000354396	  	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	  	Issued	  	2456304	  	8/19/2015	  	Spain
	10803013.1	  	7/26/2010	  	1000204918	  	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	  	Issued	  	2456304	  	8/19/2015	  	France
	10803013.1	  	7/26/2010
	10803013.1	  		  	1000342293	  	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	  	Issued	  	2456304	  	8/19/2015	  	Ireland
	10803013.1	  	7/26/2010	  	1000340517	  	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	  	Issued	  	2456304	  	8/19/2015	  	Italy
	10803013.1	  	7/26/2010
	10803013.1	  		  	1000175630	  	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	  	Issued	  	2456304	  	8/19/2015	  	Monaco
	10803013.1	  	7/26/2010	  	1000204919	  	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	  	Issued	  	2456304	  	8/19/2015	  	Netherlands
	10803013.1	  	7/26/2010
	15173016.5	  		  	1000354395	  	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	  	Abandoned	  		  		  	European Patent Office
	16174310.9	  	7/26/2010	  	1000198683	  	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	  	Abandoned	  		  		  	European Patent Office
	10803013.1	  	7/26/2010
	10803013.1	  		  	1000208590	  	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	  	Issued	  	2456304	  	8/19/2015	  	Sweden
	PCT/US2010/043240	  	7/26/2010	  	11007293	  	METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF	  	Expired	  		  		  	Patent Cooperation Treaty

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]